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Abstract 
Introduction 
Infection after lower limb arthroplasty is a serious complication with significant 
consequences for both patients and healthcare systems. Management is often challenging and 
frequently leads to a suboptimal functional outcome. Revision surgery remains a very 
expensive procedure to the patient and healthcare systems and no matter how much progress 
in diagnostic and treatment methods are achieved, the cost and morbidity of infected cases 
suggest that preventative measurements are the single most important factor in managing this 
problem. On the other hand, tertiary referral centres with well established strategies for 
treatment of infections may improve the rates of eradicating infection and overall outcomes. 
Therefore, the hypothesis of this thesis was that preventative and management strategies 
undertaken will improve the outcome of infection control. Studies included focused on 
prevention of infection but also explored the strategies and novel approaches implemented at 
University College London Hospital to improve the outcome of eradicating infection after hip 
and knee arthroplasties. 
 
Materials and Methods 
A comprehensive review of the current literature was initially conducted. This was followed 
by a number of studies to investigate prevention and treatment strategies of periprosthetic hip 
and knee joint infections: 
a) A randomised controlled trial has been conducted to compare postoperative wound 
complications of triclosan impregnated sutures and conventional non-coated sutures in 
patients undergoing primary hip and knee arthroplasties. Triclosan has been shown to 
reduce bacterial adherence to sutures and to decrease microbial viability both in vitro and 
in animal models with a high safety profile. However, the majority of evidence comes 
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from case series and trials in other surgical specialties. Hence, the aim of this study was to 
investigate whether triclosan coated sutures will reduce wound healing complications in 
hip and knee arthroplasty surgery. 
b) A meta-analysis of tranexamic acid effect on wound healing complications and infections 
after primary total hip arthroplasty has been conducted. The role of tranexamic acid in 
reducing blood loss and allogeneic blood transfusions has been previously investigated. 
However, taking into account that allogeneic blood transfusions have been linked to an 
increased rate of wound and systemic infections, I conducted this meta-analysis with the 
aim of investigating whether tranexamic acid will reduce wound healing complications 
including infections after primary hip arthroplasties which has not been previously 
studied. 
c) Late periprosthetic infections invariably lead to implant removal with a two stage revision 
strategy being the treatment of choice in most centres whereas early infections and acute 
haematogenous infections may be managed with implants retention and serial 
debridements. Accordingly, I have conducted the following studies to investigate the 
efficacy of strict strategies and novel approaches implemented over the last 10 years at 
University College London Hospital in treating PJIs: 
1) Is Single-stage Revision According to a Strict Protocol Effective in Treatment of 
Chronic Total Knee Arthroplasty Infections? The aim was to determine infection 
control rates associated with the single-stage approach when applied in a highly 
selected group of patients and compare them with results of the two-stage procedure. 
2) Periprosthetic Joint Infections after Total Hip Arthroplasty: The Ten Year Outcomes 
of an Algorithmic Approach. The aim was to present the strategy applied for 
treatment of various subgroups of periprosthetic joint infection at a centre of 
excellence and report the outcome of infection rates. 
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Results 
Contrary to the evidence from other surgical specialties that triclosan coated sutures are 
effective in preventing periprosthetic joint infections, no such effect was seen in the 
randomised controlled trial conducted. In fact, triclosan coated sutures were associated with 
higher rates of wound complications (P=0.03). 
Tranexamic acid on the other hand, led to a 3% reduction in the risk of developing wound 
complications including infections compared to the control group (Risk difference -0.03, 
95%, confidence interval CI -0.05 to -0.01, P-value 0.01). This protective effect of 
tranexamic acid against infections has not been previously reported in the literature. 
In a highly selected population, none of the 28 patients who underwent a single stage revision 
developed recurrence of infection whereas five out of 74 patients (7%) in the two-stage 
revision group developed reinfection. The results of single-stage revision in this retrospective 
study reflect the strict inclusion criteria, surgical technique and multi-disciplinary approach 
which were associated with high rates of eradicating infection. However, randomised 
controlled trials are necessary to confirm those results in comparison to other treatment 
modalities. 
The use of a strict strategy driven by an experienced multi-disciplinary team working 
simultaneously at a centre where infection is being dealt with on a regular basis has resulted 
in high rates of infection-free survival with 188 out of 204 patients (92%) achieving 
successful eradication of their infections and returning to their expected functional level with 
no evidence of recurrence or loosening, wearing away, or malpositioning on follow-up 
radiographs. This compares well with evidence from the literature confirming that centres of 
excellence only can achieve as high infection eradication rates as reported in this study. 
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Conclusion 
The results of the included studies suggest using tranexamic acid but not triclosan coated 
sutures in routine primary hip and knee arthroplasty surgery to reduce wound healing 
complications and infection. Treating periprosthetic joint infections requires a multi-
disciplinary team approach working at a tertiary centre dealing with infections on a regular 
basis. Single-stage revision in acute and chronic joint infections is appealing and gaining the 
momentum but randomised controlled trials are necessary to confirm its efficacy against 
other treatment modalities.  
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1.1 Introduction 
Periprosthetic infection in total hip (THA) and knee arthroplasty (TKA) was one of the most 
common and dangerous complications in the early years of joint replacement with a rate as 
high as 9.5% reported by Charnley. More recently, the incidence has decreased significantly 
as a result of improvements in operating room discipline, surgical technique, more assiduous 
preoperative assessment of the patient, and the prophylactic administration of antimicrobial 
agents (Kaltsas, 2004).
  
Although rates now are around one to two percent of all primary total 
joint arthroplasty (TJA) and five percent of arthroplasty revisions (Vanhegan et al., 2012b), 
the management from both the patient and surgeon perspective is challenging, often requires 
a prolonged course of treatment, is associated with a considerably increasing cost to the 
healthcare system estimated at four times the cost of a primary TJA without infection 
(Dreghorn and Hamblen, 1989), and may lead to complications such as recurrence of 
infection and septic loosening of the prosthesis (Burnett et al., 2007).  
Multiple risk factors for developing infection after TJA have been identified including length 
of the procedure, the number of previous operative interventions, rheumatoid arthritis, 
diabetes mellitus, excess alcohol intake, chronic lung and liver disease, sickle cell disease, 
obesity, poor nutrition, and immunosuppressive medications including systemic steroids, any 
history of osteomyelitis or septic arthritis and presence of open skin lesions on the affected 
extremity (Luessenhop et al., 1996, Poultsides et al., 2013, Maoz et al., 2015, Bohl et al., 
2016). 
Infection following TJA can present a diagnostic challenge as there is no gold standard for 
determining whether an infection is present or not (Della Valle et al., 2011). The treatment of 
the infected TJA leads to a long difficult course for the patient, and frequently results in a 
suboptimal functional outcome. Various treatment modalities are available depending on a 
number of factors including, the acuteness or chronicity of the infection; the infecting 
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organism, its sensitivity profile to antibiotics, and its ability to manufacture glycolyx; the 
health of the patient; the fixation of the prosthesis; the available bone stock; and the particular 
philosophy and training of the surgeon (Haddad et al., 1999). Infected TJA should be 
approached with careful preoperative assessment and a well defined treatment plan as will be 
outlined in this review of the current standards of managing periprosthetic joint infections 
(PJIs) after THA and TKA. 
1.2 Microbiologic Considerations 
Although infection after TJA may be caused by haematogenous seeding, bacteria from the 
skin flora of the patient and airborne bacteria from theatre personnel may enter the wound at 
the time of surgery as well. Many studies have demonstrated that individuals moving around 
the operating theatre contribute the largest proportion of pathogenic bacteria to the wound. As 
a result, various measures have been introduced to control the operating environment 
including the use of laminar air flow and Charnley's ultraclean air system comprising sterile 
hoods and a body-exhaust system as well as prophylactic antibiotics, which have reduced 
rates of infection from 9% to 1.3% (Charnley, 1972, Ha'eri and Wiley, 1980). Another 
important source of infection is a leaky wound postoperatively and hence the importance of 
careful handling of the soft tissues and achieving a water tight seal at the time of wound 
closure. A good understanding of potential pathogens contaminating surgical wounds is 
essential in order to use the appropriate antibiotics for prophylaxis and treatment of 
infections. In most reports of PJIs, Staphylococcus aureus and Staphylococcus epidermidis 
are the most common infecting organisms accounting for approximately 85%-90% of the 
infections (Barberan, 2006, Ribeiro et al., 2012). Some common but less frequent organisms 
include Streptococcus species and Gram negatives such as Pseudomonas, Klebsiella, and 
Escherichia coli which are usually secondary invaders of open, draining wounds in patients 
with deep sepsis of a TJA. Anaerobic microorganisms are isolated in 10% of such patients 
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(Vogelyl et al., 1996). Occasionally, the treatment of the infected arthroplasty is complicated 
by polymicrobial infections with particularly virulent organisms such as Group D 
Streptococci, Pseudomonas, fungal or mycobacterial infections which can cause a real 
challenge for the surgeon both to diagnosis and treat due to recurrent sepsis (Tian et al., 2014, 
Peel et al., 2012). Resistance of microorganisms such as Staphylococcus aureus and 
Staphylococcus epidermidis has been attributed in many reports to the ability of the organism 
to produce a slime layer, or a biofilm of glycocalyx. This layer is made up of a variety of 
polysaccharides synthesised by the bacteria as well as a range of host molecules which 
enables the organism to adhere to and survive on synthetic surfaces. Staphylococcus 
epidermidis is a usual cause of biofilm formation. Bacteria that exist within a biofilm are at 
least 500 times more resistant to antibiotics than bacteria which exist as individual free-
floating cells (Trampuz et al., 2003). On the other hand, Methicillin-resistant strains cause 4-
5% of hip and knee replacement infections (Health Protection Agency, 2016) but the 
mechanism of resistance has been attributed to an acquired genetic determinant, mecA or 
mecC which encode for a low affinity penicillin binding protein that can continue the 
catalysis of peptidoglycan transpeptidation in the presence of high concentrations of beta-
lactam antibiotics (Kim et al., 2013). 
1.3 Classification of PJI 
Classification systems are devised to help guide treatment and are primarily based on the 
onset of symptoms from the time of surgery and the route by which the infecting organism 
gains access to the joint space. Coventry (Coventry, 1975) classified infections after THA 
into three stages: acute infections which develop within three months of the surgery and are 
caused by contamination at the time of the operation (Stage I), delayed infections which are 
more indolent and may not become apparent until several months after the hip replacement 
and are also related to contamination at the time of surgery (Stage II) and haematogenous 
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infections which are associated with a previous infection remote to the hip joint such as a 
respiratory, dental and urinary tract infection and may develop soon after the remote infection 
or as late as two or even several years after the hip replacement (Stage III).  
Tsukayama (Tsukayama et al., 1996) expanded the classification into four categories to 
facilitate further the management of these patients: 1) positive intraoperative cultures from 
revision TJA without other features of obvious infection where the infection should be treated 
with six weeks of intravenous antibiotics and no operative intervention; 2) early postoperative 
infections (occurring less than 1 month postoperatively) where treatment should include 
debridement, retention of the prosthesis, and intravenous antibiotics; 3) late chronic 
infections (occurring more than 1 month postoperatively with an insidious onset) which 
requires removal of the prosthesis and a staged revision; and 4) acute haematogenous 
infections where debridement is sufficient if the prosthesis is well fixed. However, if the 
prosthesis is loose, treatment should be the same as that for a late chronic infection. 
1.4 Definition of PJI 
Over time, various definitions of surgical site infections (SSIs) including PJIs have been 
devised (Parvizi, 2011, Osmon et al., 2013, Parvizi et al., 2011c, CDC, 2015, Parvizi and 
Gehrke, 2014) to provide a platform for communication and improve treatment outcomes. 
However, a number of challenges deemed it impossible to reach a universal definition due to 
the variability of the 1) infecting organisms and their virulence, 2) hosts immune response, 3) 
criteria used for defining infection including the time of onset (early vs. late), source of 
infection (postoperative vs. hematogenous) and tissues involved (superficial vs. deep) and 4) 
diagnostic tools utilised to establish a diagnosis (Oussedik et al., 2012, Sukeik and Haddad, 
2009c). With so many variations of definitions, it has been internationally recognised that 
there is a need for a universal definition in order to compare practice and drive research and 
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to determine the optimum strategies for prevention and management of PJIs. Some of the 
more common definitions and classification systems for SSIs/PJIs are detailed in Table 1.1 
(Parvizi, 2011, Parvizi and Gehrke, 2014, CDC, 2015, Oussedik et al., 2012, Wilson et al., 
1986, Parvizi, 2010, Osmon et al., 2013). 
The National Institute of Clinical Excellence (NICE, 2003) in the United Kingdom provides 
guidelines on the management of wound infections and bases its definition of an SSI on that 
agreed by the Center for Disease Control (CDC). NICE also recognises the ASEPSIS wound 
scoring system which was devised by Professor Wilson at University College London 
Hospital in 1986 (Wilson et al., 1986, Wilson et al., 1990) for postoperative surveillance of 
wound healing and effectiveness of antibiotic treatment after infections. ASEPSIS provides 
the advantage of a very detailed assessment of the surgical wound but can be quite time 
consuming to fill out on day to day clinical assessment. (Table 1.1) 
The Société de Pathologie Infectieuse de Langue Française (SPILF) organised a consensus 
meeting with other French speaking recognised bodies including the French Society of 
Orthopaedics and Trauma Surgery and The French Society of Anesthesiology and Intensive 
Care. A definition of PJI was agreed and this provided a platform for communication of 
clinical practice and research within the French speaking world (SPILF, 2010). (Table 1.1) 
In 2010, The American Academy of Orthopaedic Surgeons (AAOS) developed guidelines 
and an evidence report on the management of PJI (Parvizi, 2010). The working party 
involved in developing these guidelines included members of the CDC and experts in the 
field. The guidelines described two categories: high and low probability of PJI depending on 
risk factors and clinical and radiological evidence. An algorithm for clinical tests was 
provided but without specific cut off values for these tests. (Table 1.1) 
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Following that, The Infectious Diseases Society of America (IDSA) described the presence of 
a sinus tract in communication with the joint as a definitive criterion and histopathological 
findings when present as highly suggestive of infection. They also described the work up 
required prior to this including a history with a particular reference to pain and investigations 
including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), arthrocentesis and 
blood cultures. However, specific values suggesting the relevance of these results were not 
provided. (Table 1.1) 
Almost simultaneously with the IDSA, The Musculoskeletal Infection Society (MSIS) 
convened to establish a definition of PJI to be used by recognised bodies including the CDC 
as a gold standard for communication. This definition includes major and minor criteria that 
can easily be measured and members of the CDC were also on the panel (Parvizi et al., 
2011b). (Table 1.1) 
Professors Thorsten Gehrke and Javad Parvizi recognised that the longstanding issue with the 
prevention and treatment of PJIs was that although much research into the topic had been 
undertaken, there was a failure to answer fundamental questions about the subject due to lack 
of high level evidence. Therefore, they organised the International Consensus Meeting on PJI 
in Philadelphia in 2013 with the aim of answering some of these important questions. An 
outcome of this meeting was the creation of a definition for PJI, constituting 2 major and 5 
minor criteria. This definition was formulated on the basis of existing evidence and a 
consensus of expert opinions. The presence of at least 1 major criterion or 3 minor criteria is 
required for a diagnosis of PJI. This includes analyses of tissue and aspirate cultures, 
laboratory tests such as ESR, CRP, polymorphonuclear (PMN) percentage, and synovial fluid 
white cell count (WBC) and neutrophil count on microscopy. The same definition was then 
adopted by the CDC with clarification of the definition of matching organisms and 
appropriate tissue sampling. CDC also stated that the laboratory cutoffs quoted in this 
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definition should not guide clinicians in the actual clinical diagnosis of infection but instead, 
they should refer to the MSIS consensus definition for clinical use (CDC, 2015). (Table 1.1) 
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Table 1.1 A summary of common surgical site and periprosthetic joint infection definitions 1 
Study Definition +ve -ve 
ASEPSIS 
(Wilson et al., 
1986) 
A scoring method for post operative wound infections for use in clinical trials 
A score of 1 to 5 is given for each of the following parameters dependent on the proportion of 
wound affected: 
-serous exudate 
-erythema 
-purulent exudate 
-separation of deep tissues 
Additional points are then given for: 
-antibiotic use 
-drainage of pus under local anaesthetic 
-debridement of wound under general anesthetic 
-serous discharge 
-erythema 
-purulent exudate 
-separation of deep tissues 
-isolation of bacteria 
-inpatient stay more than 14 days 
 
Recognised by NICE as 
a valid measure for 
assessment of surgical 
site infection 
 
 
Score is time consuming to 
carry out in daily clinical 
practice 
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Score   Meaning 
0 to10   No infection 
  Normal healing 
11 to 20  Disturbance of healing 
21 to 30  Minor infection 
31 to 40  Moderate infection 
≥ 41   Severe infection 
(SPILF, 2010) Classification according to aetiology, location and duration 
Diagnosis: Presence of a fistula close to the prosthesis confirms infection until proven 
otherwise 
Post operative signs suggestive of infection: 
- unusually strong pain or its recurrence after a symptom free period 
- purulent discharge from a surgical wound 
- disunion, necrosis or scar inflammation 
- general signs of fever 
- radiological appearance of loosening 
Biological signs: 
WBC is not a good positive or negative predictor of infection 
Normal ESR and CRP do not exclude infection 
CRP should be used for monitoring of infection 
Suspect infection with ESR >30mm and CRP >13.5mg/l 
Includes physical signs 
 
Provides biological 
parameters 
 
Describes imaging 
techniques for diagnosis 
Specificity and sensitivity of 
biological parameters not given 
 
High level of clinical suspicion 
may lead to over diagnosis of 
PJI 
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Imaging modalities: 
CT, MRI, US and nuclear medicine imaging suggestive of infection 
AAOS 
(Parvizi, 2010) 
 
High probability of infection: 
One or more symptom AND at least one or more of the following: 
Risk factors (supported by evidence or expert opinion), physical exam findings (e.g. warmth, 
effusion, redness, swelling or a sinus tract associated with the joint) or radiological evidence 
of implant loosening/osteolysis 
Low probability of infection: 
Pain or joint stiffness only and no risk factors, physical examination findings or radiological 
evidence of implant loosening /osteolysis 
Algorithm provided for  clinical tests: 
If ESR and CRP raised joint aspiration is recommended 
If joint aspiration provides positive differential cell count and positive culture – infection is 
likely 
If only one of the above is positive repeat aspiration and if positive infection is likely 
If second aspiration is negative and surgery is planned frozen section is recommended 
Applicable to hip and 
knee surgery only 
 
Risk factors included 
 
Physical signs included 
 
Useful algorithm  
 
Amount of samples for 
aspirate/culture may miss 
diagnosing some PJIs 
IDSA (Osmon 
et al., 2013) 
Definite: 
1) Sinus tract communicating with the prosthesis 
2) There is purulence around the prosthesis without any other known cause 
 
Highly suggestive: 
1) Acute inflammation on histopathologic examination of periprosthetic tissue at the time of 
surgical debridement OR prosthesis removed is highly suggestive of PJI as defined by 
the attending pathologist 
2) >2 Intra-operative cultures yielding same organism, OR combined aspiration and culture 
3) Cultures grow a virulent microorganism from tissue or synovial fluid samples 
Clear information 
stipulates that at least 3 
or optimally 5 
periprosthetic samples 
OR explanted prosthesis 
should be submitted for 
anaerobic and aerobic 
cultures 
 
Antibiotics should be 
In the absence of a skilled 
pathologist PJI may be missed 
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Additional information 
- PJI can be present if the given criteria are not met. All available information should be taken 
into account when diagnosing PJI 
- Intra-operative diagnosis is reliable when interpreted by a skilled pathologist 
withheld for 2 weeks 
prior to cultures being 
taken if possible 
MSIS (Parvizi 
et al., 2011b) 
Major criteria: 
1) there is a sinus tract communicating with the prosthesis; or  
2) a pathogen is isolated by culture from 2 or more separate tissue or fluid samples obtained 
from the affected prosthetic joint; or  
 
Minor criteria: 
3) when 4 of the following 6 criteria exist:  
a. elevated ESR and CRP   
b. elevated synovial WBC   
c. elevated synovial PMN percentage  
d. presence of purulence in the affected joint   
e. isolation of a microorganism in one culture of periprosthetic tissue or fluid, or   
f. greater than 5 neutrophils per high-power field in 5 high-power fields observed from      
histologic analysis of periprosthetic tissue at ×400 magnification 
 
Additional Information 
Please note that a PJI may be present if less than 4 of these criteria are met  
 
  
International 
consensus 
group 
(Gehrke and 
Major criteria: 
1) A sinus tract communicating with the joint; or 
2) 2 positive phenotypically identical organisms on cultures taken in periprosthetic 
sampling; or 
Accompanying 
declaration states 
infection may be 
present when these 
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Parvizi, 2014) 
 
 
 
 
 
Minor Criteria: 
3) when 3 of the following 5 criteria exist: 
a. elevated ESR & CRP 
b. elevated synovial fluid WCC OR ++ change on leucocyte esterase test strip 
c. elevated synovial fluid PMN% 
d. a single positive culture 
e. positive histological analysis of periprosthetic tissue 
criteria are not met 
 
Further stipulation of 
values of the minor 
criteria is given 
according to acuteness 
or chronicity of 
infection 
(CDC, 2015) Major Criteria: 
1) A sinus tract communicating with the joint; or 
2) 2 positive periprosthetic tissue or fluid cultures with matching organisms; or 
 
Minor Criteria: 
3) when 3 of the following 5 criteria exist: 
a. CRP >100mg/L AND ESR >30mm/hr 
b. synovial fluid WCC >10,000 cells/μL OR ++ change on leucocyte esterase strip test 
of synovial fluid 
c. elevated synovial fluid PMN percentage (>90%) 
d. a single positive periprosthetic tissue or fluid culture 
e. positive histological analysis of periprosthetic tissue (more than 5 PMNs per high 
power field) 
 
Additional Information 
Further details given about: 
1) definition of matching organism 
2) positive cultures of hardware from a hip or knee can be used to meet criterion 2  
3) definition of sinus given 
 
 
 
Specific for hip and 
knee replacement only 
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1.5 Prevention of PJIs 
1.5.1 Antibiotic Prophylaxis 
Prophylactic antibiotics are defined as those given before, during or after surgery to prevent 
infection. Current UK practice suggests that prophylactic antimicrobial agents should cover 
expected pathogens, take into account local resistance patterns and have a narrow spectrum 
whilst considering cost (SIGN, 2014). The role of antimicrobial prophylaxis has been 
established to be the single most significant factor in the prevention of deep wound infection 
following TJA (Hanssen and Osmon, 1994). Meehan (Meehan et al., 2009) investigated the 
optimal time for prophylactic antibiotic administration in an animal model and reported that 
bactericidal action was most effective when antibiotics were present within tissues prior to 
surgery. Current guidance obtained from consensus between the CDC and AAOS 
recommends administration of prophylactic antibiotics an hour prior to incision and 
continuing antibiotics for 24 hours postoperatively (Illingworth et al., 2013). However, NICE 
and SIGN guidelines suggest a single dose except in special circumstances such as prolonged 
surgery or major blood loss (SIGN, 2014). Cephalosporins including cefuroxime and 
cefazolin are the most commonly prescribed prophylactic antibiotics as per AAOS 
recommendation due to broad spectrum coverage against penicillinase producing methicillin 
susceptible Gram positive Staphylococci and Streptococci. Alternatives for allergic patients 
include clindamycin, teicoplanin and vancomycin (Osmon et al., 2013). There are numerous 
benefits to using cephalosporins as they cover most organisms encountered in orthopaedic 
surgery. Furthermore they have a proven evidence base, good safety profile and are 
inexpensive. In the UK, there has been a trend though towards avoiding cephalosporins due 
to the high rates of associated Clostridium difficile infections (Aujla et al., 2013). Al-Maiyah 
(Al-Maiyah et al., 2005) reported an increased resistance of coagulase (-) Staphylococci to 
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cephalosporins and recommended a revised prophylaxis strategy avoiding cephalosporins. 
However, it is worth noting that their conclusion may be related to the extensive usage of 
cephalosporins as a first line drug for prophylaxis in joint replacement surgery. Furthermore, 
a recent review examining the potential association of Clostridium difficile infections 
with cephalosporins showed no clear association between overall cephalosporin prescribing 
(or the use of any particular cephalosporin) and Clostridium difficile incidence. Hence, other 
factors should be assessed rather than focusing on the exclusion of individual drug classes 
(Wilcox et al., 2017). AlBuhairan (AlBuhairan et al., 2008) showed in a systematic review of 
antibiotic prophylaxis in joint arthroplasty that there is no evidence that any type of antibiotic 
prophylaxis has better results than any others and that selection should be on the basis of cost 
and local availability. Cranny (Cranny et al., 2008) reported that there is insufficient evidence 
to determine whether there is a threshold prevalence of Methicillin Resistant Staphylococcus 
aureus (MRSA) at which switching from non-glycopeptide to glycopeptide antibiotic 
prophylaxis might be clinically effective and cost-effective. Furthermore, the AAOS suggests 
routine antibiotic prophylaxis for 2 years following THA prior to various procedures 
associated with significant risk of bacteraemia such as dental cleaning and extraction (Parvizi 
and Della Valle, 2010).  
The prophylactic role of antibiotic loaded cement (ALC) in primary TJA has also been 
assessed in prospective studies in over 1600 cases. In data from the Scandinavian arthroplasty 
registers, with an exhaustive follow-up of more than 240000 hip replacements, infection rate 
was reduced by 50%. Human pharmacokinetics during THA showed antibiotic 
concentrations 20 times the minimal inhibitory concentration (MIC) in drainage fluids. No 
toxic concentrations have been detected in blood or urine, and no allergies, toxic effects, 
mechanical failures or selection of resistant microorganisms have been observed. Therefore, 
ALC prophylaxis is now widely used in countries with prostheses registers. Antibiotics leach 
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from Palacos bone cement in higher concentrations and for longer periods than from 
Simplex-P, CMW, and Sulfix acrylic bone cements (Penner et al., 1999). Furthermore, 
Palacos with gentamicin is more resistant to fracture than Zimmer or Simplex-P cement 
mixed with gentamicin (Callaghan et al., 1985). The most commonly used antibiotics in ALC 
include tobramycin, gentamicin and vancomycin (Scott and Higham, 2003). The combination 
of vancomycin and one of the aminoglycosides provides a broad spectrum of coverage for 
organisms commonly encountered with deep periprosthetic infections. The presence of 
tobramycin has a synergistic like effect on the bactericidal activity of vancomycin. A low 
dose of ALC not exceeding 10% of the cement weight should be used for prophylaxis. 
However, when used in treatment of infected THA, ALC is used in higher doses as an 
adjuvant to excision of infected and devascularised tissues and systemic antibiotic treatment 
(Langlais et al., 2006).  
Antimicrobial coated sutures have also been widely used to prevent microbial colonisation of 
suture material in operative wounds (Barbolt, 2002). For example, the coated Vicryl Plus 
triclosan (polyglactin 910) suture was developed and approved by the Food and Drug 
Administration (FDA) in 2002. Triclosan is a broad-spectrum antiseptic which has been 
widely used in humans for more than 30 years (Barbolt, 2002) and is effective against 
Staphylococcus aureus and Staphylococcus epidermidis including methicillin-resistant 
strains, vancomycin-resistant Enterococcus faecalis, Pseudomonas aeruginosa, and 
Escherichia coli (Edmiston et al., 2006, Rothenburger et al., 2002). Vicryl Plus sutures (VPS) 
have recently been shown to reduce bacterial adherence to sutures and to decrease microbial 
viability both in vitro and in animal models (Edmiston et al., 2006, Gomez-Alonso et al., 
2007, Rothenburger et al., 2002, Storch et al., 2002a, Storch et al., 2002b) with a high safety 
margin, little or no risk of allergic reactions and no evidence of microbial resistance (Barbolt, 
2002, Gilbert and McBain, 2002). However, the majority of evidence is related to studies in 
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general surgery and no trials to date have been published in Orthopaedics and lower limb 
arthroplasty. 
1.5.2 Blood Management 
Numerous studies have shown that allogeneic blood transfusion increases the risk of SSI 
through the mechanism of immunomodulation (Bloch et al., 2013). Moreover, rates of SSI 
and lower and upper respiratory tract infections were increased after elective TJA in patients 
receiving allogeneic blood transfusion compared with patients who did not receive blood 
transfusion (Friedman et al., 2014). On the other hand, the role of autologous transfusion in 
the risk of developing SSI and PJI remains inconclusive. Taken together, much effort should 
be exercised perioperatively to reduce the need for any type of blood product transfusion. A 
variety of blood-conserving techniques have been developed to decrease blood loss and 
postoperative transfusion rates including controlled hypotension, regional anaesthesia, 
intraoperative blood salvage, erythropoietin and antifibrinolytic agents such as tranexamic 
acid. However, the direct relationship between using these techniques and reducing wound 
complications and infections have not been adequately explored in the literature. 
1.5.3 Other Measures 
Other measures to prevent infection include stopping smoking and excessive alcohol 
consumption (Bradley et al., 2007, Moller et al., 2002, Singh, 2011), weight loss in the obese 
and control of comorbid diseases such as diabetes, sickle cell disease, liver and kidney 
dysfunction and rheumatoid arthritis (Marchant et al., 2009, Cohen et al., 2005, Shrader et al., 
2006, Doran et al., 2002). Temporary cessation of medications such as methotrexate also 
decreases the risk (Bridges et al., 1991)
 
although this needs to be balanced against the risk of 
a rheumatoid flare. In theatre, staff should be kept to a minimum (Malinzak and Ritter, 2006), 
appropriate use of gowns, face masks, double gloving, hand-washing, skin preparation and 
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temperature regulation should always be implemented and duration of surgery should be kept 
as short as possible. The use of pulsatile lavage has also been reported to remove up to 87% 
of all organisms from wounds (Hope et al., 1989). In the perioperative period, periodontal 
and urinary tract sepsis must be eradicated early to prevent haematogenous seeding of the 
prosthesis (Della Valle et al., 2004). Screening for MRSA and decolonisation of carriers have 
also been linked to a reduction in MRSA surgical wound infections and bacteraemia 
(Keshtgar et al., 2008). 
1.6 Diagnosis of PJI 
1.6.1 History and Physical Examination 
A thorough history and physical examination are important to identify the type of PJI 
encountered and assess patient’s risk factors and suitability for surgical treatment. Acute 
infection according to Tsukayama (Tsukayama et al., 1996) presents within 4 weeks of the 
index procedure and is characterised by continuous pain and an erythematous, swollen and 
fluctuant wound with purulent discharge and occasional wound dehiscence. Systemic 
symptoms such as fever and chills may also occur. Chronic infection on the other hand, 
occurs after 4 weeks from the index procedure (Tsukayama et al., 1996) and is characterised 
by gradual deterioration of function, persistent pain from the time of the operation and a 
draining sinus. Relevant history includes prolonged wound discharge and wound healing after 
multiple courses of antibiotics. A previous history of infection is also important especially in 
tuberculosis where reactivation of infection may occur after a prolonged period of 
quiescence. Haematogenous infection can occur at any time after the index operation 
(Tsukayama et al., 1996) and typically involves a prosthesis that has been functioning well 
for months or years. The most frequent primary seeding site is skin and soft tissue infections 
(Zimmerli and Moser, 2012). However, other sources of infection may include the urinary, 
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respiratory, and gastrointestinal tract, as well as recent dental work (Maderazo et al., 1988). 
This type of infection is more likely to occur in immunocompromised patients and hence the 
importance of carefully assessing this subset of patients for comorbidities such as diabetes, 
chronic renal impairment, inflammatory arthropathy and malignancies.  
Early diagnosis of PJI in a well fixed implant may allow salvage of the prosthesis using an 
aggressive early debridement strategy with exchange of modular components whereas a delay 
in  diagnosis or in the case of chronic infections, a single or staged exchange procedure may 
be more appropriate to eradicate the infection. In either case, rapid intervention based on 
thorough assessment has been deemed a primary prognostic factor for successful treatment of 
infection as it may prevent biofilm formation by the infecting bacteria (Moyad et al., 2008). 
 1.6.2 Serological Tests 
The WBC and PMN percentage have been found to have a minimal role in routine workup of 
patients with suspected PJI due to low sensitivity and specificity (Toossi et al., 2012, 
Spangehl et al., 1999). However, the CRP and ESR should be used as a screening tool for all 
patients with suspected infection. The CRP level reaches maximum values within 48 hours 
from surgery and returns to normal within 3 weeks whereas ESR may remain elevated for 
months post surgery (Shih et al., 1987, Moyad et al., 2008). Therefore, an elevated CRP is 
more accurate in identifying infection (Haaker et al., 2004). A CRP level of > 10 mg/L and an 
ESR level of >30 mm/hr correlated with PJI in all THAs that were complicated by deep 
infection in two studies (Spangehl et al., 1999, Schinsky et al., 2008). As a result, authors 
recommended combining both tests to improve the accuracy of diagnosing infection. It is 
important though to recognise that ESR and CRP are nonspecific markers of inflammation 
and that they are frequently elevated in other inflammatory and infectious conditions as well 
as malignancy which may cause false positive results for PJI. Additionally, they are elevated 
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in the early postoperative period after a routine hip or knee replacement. Therefore, Bedair 
(Bedair et al., 2011) and Yi (Yi et al., 2014) defined the threshold values for CRP in acute 
postoperative PJIs of the hip and knee as 93 and 95mg/L respectively. Greidanus (Greidanus 
et al., 2007) suggested that both ESR (sensitivity, 0.93; specificity, 0.83; positive likelihood 
ratio, 5.81; accuracy, 0.86) and CRP (sensitivity, 0.91; specificity, 0.86; positive likelihood 
ratio, 6.89; accuracy, 0.88) have excellent diagnostic test performance. In a recent study of 
320 PJIs, Zajonz (Zajonz et al., 2015) showed no differences between hip and knee 
arthroplasty patients regarding levels of inflammatory markers. Parvizi (Diaz-Ledezma et al., 
2014) suggested in a recent study that the best diagnostic strategy after confirming abnormal 
CRP and ESR levels would be a diagnostic aspiration of the joint. On the other hand, the 
AAOS Clinical Practice Guidelines on PJIs (Parvizi and Della Valle, 2010) suggest that even 
normal levels of ESR and CRP do not rule out PJI, and that these tests alone should not be 
relied on for definite exclusion of PJI. 
Serum Interleukin-6 (IL-6) and procalcitonin have also been investigated and were initially 
presented as valuable markers for detecting PJIs (Berbari et al., 2010, Di Cesare et al., 2005, 
Shaikh et al., 2015). However, recent studies showed no superiority of either test over CRP in 
diagnosing infection (Glehr et al., 2013, Drago et al., 2011, Yuan et al., 2015). Additionally, 
studies relating to IL6 have been criticised for not accounting for the confounding influence 
of previous antibiotic use and associated inflammatory conditions on IL6 performance 
(Berbari et al., 2010, Di Cesare et al., 2005). 
Other serum biomarkers elevated in PJI which are under investigation for future application 
include tumour necrosis factor (TNF)-α, short-chain exocellular lipoteichoic acid, soluble 
intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 (Chen et al., 
2014). 
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1.6.3 Synovial Fluid Tests 
Hip and knee aspirations are performed using the surgeon’s preferred technique. However, a 
strict aseptic approach is essential to reduce false positive results and prevent iatrogenic 
periprosthetic infection. Fluoroscopic guidance is usually utilised for the hip joint but 
ultrasound guided hip aspirations have also been reported (Battaglia et al., 2011). Local 
anaesthetic and contrast material should be avoided due to the potential bactericidal effect 
and associated false negative results (Ali et al., 2006, Schmidt and Rosenkranz, 1970). 
Similarly, it is recommended that patients stop any antibiotics for a minimum of 2 weeks 
prior to obtaining synovial fluid or cultures to avoid false negative results (Della Valle et al., 
2011). However, in case antibiotics are continued to avoid uncontrolled recurrence of the 
infection, it is also possible to analyse the synovial WBC and perform a PCR to investigate 
infection or use biomarkers such as α-Defensin which does not seem to be affected by 
continuation of antibiotics (Deirmengian et al., 2014). The synovial fluid should be sent for 
microbiologic cultures, WBC count and differentials. Blood culture flasks should be used for 
the synovial fluid (Font-Vizcarra et al., 2010), and specialised media are required for 
suspected atypical infections, such as Lowenstein-Jensen media for mycobacteria (Woods, 
2002) or Sabouraud’s dextrose agar for fungi (O'Shaughnessy et al., 2003). Prolonged culture 
incubation for 14 days may be required if P. acnes, fungi or mycobacterium are suspected 
(Schafer et al., 2008, Larsen et al., 2012). However, cultures for mycobacterium and fungi 
should not be done routinely as this would not be cost-effective (Tokarski et al., 2013). If the 
culture results are negative in the setting of elevated synovial and serum markers suggestive 
of infection, repeat aspiration should be performed prior to surgery or initiation of 
antimicrobial treatment (Barrack et al., 1997). The optimal cut-points of synovial WBC 
count, PMN percentage and serum CRP levels for diagnosing acute and chronic hip and knee 
PJIs are detailed in Table 1.2 (Bedair et al., 2011, Yi et al., 2014, Parvizi et al., 2011b). 
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Table 1.2 Laboratory Threshold Values for Periprosthetic Joint Infection of the Knee and Hip 
 
         Acute 
 
            Chronic 
 TKA THA TKA THA 
Serum CRP (mg/L) 95 93 10 10 
Synovial WBC Count 
(cells/µL) 27,800 12,800 1100 to 4000 3,000 
Synovial PMN Cells 
(%) 89 89 64 to 69 80 
 
TKA = total knee arthroplasty; THA = total hip arthroplasty; CRP = C-reactive protein;  
WBC = White blood cell; PMN = polymorphonuclear 
 
Leucocyte esterase (LE) testing is reported to be cheap, easily applicable with high sensitivity 
(80%) and specificity (100%) rates (Parvizi et al., 2011a). However, it is important to 
remember that the presence of blood in the synovial fluid aspirates, may negatively affect the 
interpretation of the LE strip but that centrifuging the sample overcomes this problem without 
affecting the accuracy of the test (Aggarwal et al., 2013, Wetters et al., 2012). 
Synovial CRP and IL-6 have also been proposed to improve diagnostic accuracy in PJI. For 
example, combined measurement of synovial CRP and α-Defensin levels demonstrated a 
sensitivity of 97% and a specificity of 100% for the diagnosis of PJI and correctly diagnosed 
99% of cases as aseptic or infected (Deirmengian et al., 2014). However, despite some 
studies suggesting a superiority of synovial CRP over serum CRP (Parvizi et al., 2012, 
Jacovides et al., 2011), a recent report suggested that synovial CRP does not offer a 
diagnostic advantage in detection of PJIs (Tetreault et al., 2014). Randau (Randau et al., 
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2014) suggested that synovial IL-6 is a more accurate marker than serum WBC and CRP for 
the detection of PJIs and that combining serum and synovial IL-6, compared with performing 
each test individually improves the diagnostic yield. Recent studies have also shown that 
synovial IL-6 has high specificity and accuracy even when patients who were taking 
antibiotics and those with systemic inflammatory diseases were included (Deirmengian et al., 
2010, Jacovides et al., 2011). 
Other synovial biomarkers elevated in PJI which are under investigation for future 
application include cytokines such as IL-1β, IL-6, IL-8, IL-17, TNF-α, interferon-δ, and 
vascular endothelial growth factor, human β-defensin-2 (HBD-2) and HBD-3, and 
cathelicidin LL-37 (Chen et al., 2014). New technologies based on synovial fluid biomarker 
analysis, biofilm targeting and the application of metabolomics are currently underway. This 
includes biofilm visualisation and sequencing-based biomolecular methods, PCR-based 
electron spray ionization time-of-flight mass spectrometry (ESI-TOF-MS) and matrix-
assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF/MS) 
(Bizzini et al., 2010, Jacovides et al., 2012). 
1.6.4 Imaging Modalities 
Plain radiographs should be included in any workup for infected joint replacements.  
However, they are neither sensitive nor specific for detection of infection. Radiographic 
findings including loosening and osteolysis are common to both septic and aseptic failures. 
On the other hand, periosteal new bone formation and endosteal scalloping, are more 
suggestive of infection but are not seen in all cases (Spangehl et al., 1999). 
Computed tomography (CT) provides detailed analysis of bony structures and may show 
evidence of soft tissue collections. However, it is  limited due to metal artefact, is associated 
with low sensitivity for detecting PJI and exposes patients to high doses of radiation 
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alongside the significant cost associated with using them (Cyteval et al., 2002). Magnetic 
resonance imaging (MRI) is also limited due to metal artefact and studies relating to accuracy 
of metal artefact reduction sequence (MARS) MRIs are limited in the literature (Talbot and 
Weinberg, 2015). 
Scintigraphy studies may be helpful when results of serologic tests are falsely elevated due to 
inflammatory conditions and cultures of synovial fluid are unreliable because of 
administration of antibiotics or in the case of a dry tap especially if the patient is not planned 
for surgery (Enayatollahi and Parvizi, 2015). However, the cost of a scan is significant and 
comparable to that of a CT or MRI scan, the amount of radiation is equivalent to a CT scan, 
and results can remain positive for as long as one year after a knee or hip arthroplasty due to 
the increased uptake from the surgery itself. A number of isotopes including Technetium-
99m, Gallium-67 citrate, and Indium-111-labelled WBCs have been used with variable 
sensitivities and specificities in detecting PJIs. Ouyang (Ouyang et al., 2014)
 
reported in a 
recent systematic review that overall sensitivity and specificity for using triple phase bone 
scans to detect PJI was 0.83 and specificity was 0.73. However, the sensitivity and specificity 
for detecting infected arthroplasty of the hip (0.81 and 0.78, respectively) were significantly 
higher than those of the knee (0.75 and 0.55, respectively; p < 0.05). A meta-analysis of 
antigranulocyte scintigraphy with monoclonal antibodies studying PJI in THAs showed 
sensitivity and specificity of 83% and 80%, respectively (Pakos et al., 2007). On the other 
hand, sensitivity of Indium-111-labelled WBC labelled scans for detecting periprosthetic hip 
infections has been reported as low as 50% in the literature (Pill et al., 2006).   
Fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PET) has been investigated 
over the last decade for a role in diagnosing PJIs. The investigation relies on the fact that 
inflammatory cells express more glucose transporters, resulting in intracellular accumulation 
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of deoxyglucose which cannot be metabolised by the cell and can be identified by PET 
imaging. Although a meta-analysis conducted in 2006 by Prandini et al (Prandini et al., 2006) 
reported a sensitivity of 94.1 % and a specificity of 87.3% for detecting PJI, another meta-
analysis in 2008 (Kwee et al., 2008) reported the overall diagnostic performance of FDG-
PET as moderate to high and warned about heterogeneity of studies available in the literature. 
Two further studies published over the last 3 years (Brammen et al., 2015, Gemmel et al., 
2012) suggested that the role of FDG-PET in diagnosing PJI is still to be determined. It is 
worth noting as well that this type of imaging is currently only available in tertiary referral 
centres and that it costs three times the cost of a bone scan or MRI (Hsu and Hearty, 2012). 
1.6.5 Intraoperative Assessment 
Intraoperative assessment at the time of revision surgery starts with evaluating the tissue 
appearance and classically performing gram stains of fluid or tissue samples collected. 
However, it is important to recognise that neither tissue appearance nor gram staining are 
reliable indicators for ruling in or ruling out infection (Della Valle et al., 2004, Spangehl et 
al., 1999).  
Intraoperative frozen sections have been reported as useful methods for detecting PJI in 
patients planned for revision surgery when other tests have been suggestive but not 
conclusive of infection (Enayatollahi and Parvizi, 2015). Samples from deep tissues including 
the interfaces between bone and cement and cement and the implant should be sent for 
analysis. An experienced pathologist is essential to interpret the results according to the 
number of WBCs visualised per high power field. A study of 175 revision arthroplasties 
recommended using 10 WBCs/high power field as a threshold for diagnosing infection with a 
sensitivity of 0.84 and specificity of 0.99 (Lonner et al., 1996). MSIS/CDC guidelines 
recognise more than 5 PMNs per high power field as a minor diagnostic criterion for PJI 
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(Parvizi et al., 2011b). A recent study suggested that at the time of second-stage 
reimplantation surgery, frozen section is useful in ruling in infection, where the specificity is 
94%; however, there is less utility in ruling out infection, because sensitivity is only 50% 
(George et al., 2015). Intraoperative synovial fluid sampling follows the same principles as 
preoperative synovial fluid sampling as outlined previously. 
Intraoperative cultures are presumed to be the gold standard for identifying PJI. However, 
they are subject to false-negative and false-positive results (Tsukayama et al., 1996). As with 
joint aspiration, careful technique and withholding antibiotics for at least 2 few weeks 
preoperatively are essential to reduce false negatives (Della Valle et al., 2011). The definitive 
diagnosis of PJI is made when the same organism is isolated from at least 2 intraopearive 
cultures (Parvizi et al., 2011b). However, various studies suggest that 3-6 samples are 
collected from superficial, deep and periprosthetic tissues in order to obtain an accurate 
diagnosis of infection (Atkins et al., 1998, Parvizi et al., 2009, Parvizi et al., 2011b). The 
explanted component should also be sent to the microbiology lab for sonication as this 
improves sensitivity of the cultures from 61-78% even with patients who are receiving 
antibiotic treatment (Trampuz et al., 2007). Furthermore, the use of sonication in combination 
with other diagnostic techniques, such as multiplex PCR, can improve the identification of 
bacteria compared with conventional methods (Portillo et al., 2012, Achermann et al., 2010). 
The incubation period for cultures should be at least 7 days. However, reports published 
recently suggest prolonging incubation for 14 days as this increases the chances of 
identifying organisms that otherwise may remain culture negative (26.4% additional cases 
were classified as infected at 14 vs. 7 days) (Schafer et al., 2008, Larsen et al., 1995).  
In 10-15% of cases, despite the presence of clear signs for infection including gross 
purulence, cultures may still be negative (Parvizi et al., 2006). Possible causes may be 
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inappropriate collection of samples, short incubation duration and the use of antimicrobial 
therapy prior to samples collection. Interestingly though, Ghanem (Ghanem et al., 2007) 
demonstrated that the administration of preoperative antibiotics to patients with a positive 
preoperative joint aspirate did not interfere with the isolation of the infecting organism more 
than when antibiotics were stopped. Therefore, it is paramount to liaise carefully with 
microbiologists to facilitate rapid and accurate analysis of intraoperative samples. The 
identification of specific pathogens using PCR-based assays was originally investigated to 
improve identification of organisms that caused an infection. Earlier PCR-based assays 
however, led to a higher rate of false-positives due to contamination and higher false-
negatives because the probes used could not cover the wide spectrum of pathogens 
responsible for infection. However, there are novel systems which aim to improve 
identification of organisms responsible for PJI such as the Ibis T5000 biosensor system which 
uses a pan-domain DNA-based amplification technique (Jacovides et al., 2012). In one study, 
Ibis T5000 was not only able to verify positive conventional culture results, but was also able 
to detect an organism in four out of five cases of PJI that was thought to be culture-negative. 
Additionally, Ibis found that 88% of the revision cases that were presumed aseptic were 
actually cases that had a subclinical infection (Jacovides et al., 2012). 
1.7 Management of PJI 
The goals of treatment are the eradication of infection and the restoration of function of the 
affected limb. Treatment options include: debridement with retention of components, single-
stage revision, two-stage revision, multi-stage revision and long term suppressive antibiotics 
or salvage procedures in patients with high operative risk. The extent of infection and the 
interval for which it has been present play a role in the choice of the revision procedure and 
the chances for successful treatment following revision. Classifying infection into acute or 
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late infection aids in the treatment plan. Treatment of mycobacterial infections follows the 
same guidelines (Boeri et al., 2003). 
1.7.1 Acute Infection 
Debridement with component retention: Irrigation and debridement with or without exchange 
of mobile parts (femoral heads and acetabular inserts) and retention of the infected implant 
has been advocated for early or late infections with a short duration of symptoms, stable 
components, and overlying soft tissue and skin of good condition (Davis, 2005, Zimmerli et 
al., 2004). The aim of rapid intervention with thorough debridement is to prevent the 
production of any biofilm by the infecting organism which is paramount for a successful 
outcome (Crockarell et al., 1998). Difficulties with this approach include determination of the 
time of onset of infection and the establishment of a point beyond which it is no longer 
reasonable to retain the implant. Despite expeditious management with irrigation and 
debridement, acute TJAs may lead to recurrent infections. Success rates in the literature range 
between less than 10% and more than 60% (Crockarell et al., 1998, Deirmengian et al., 
2003). Thus, patients should be advised that other options of treatment may be necessary in 
case of an unsuccessful attempt at retaining the prosthesis including a staged revision or 
salvage procedures.  
1.7.2 Chronic Infection 
In chronic infections, a successful outcome depends on several factors including the baseline 
health status of the patient, implant removal with a thorough debridement followed by culture 
specific antibiotic treatment postoperatively. During this period the laboratory and clinical 
signs of the infection must return back to normal. Reimplantation can either be performed at 
the same stage as the debridement as part of a single-stage procedure, or alternatively as part 
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of a two or multi-stage procedure where debridement and reimplantation are separated by a 
period of antibiotic delivery (Krbec et al., 2004, Mitchell et al., 2003).  
1.7.2.1 Single-stage Revision 
Advantages of simultaneous debridement and exchange of the prosthesis include the 
avoidance of additional surgical procedures in patients who have major medical problems, for 
whom the risks of additional procedures are cumulative. Success rates for eradication of 
infection with single-stage revisions ranged between 76-82% in most studies when antibiotic 
loaded cement has been utilised in comparison to only 58% without using it (Buchholz et al., 
1981, Raut et al., 1995, Sanzen et al., 1988). However, Jackson (Jackson and Schmalzried, 
2000) in a review of the literature reported that the indications for direct exchange are limited 
by several factors including: 1) Failures associated with (a) polymicrobial infection; (b) 
gram-negative organisms, especially Pseudomonas species; and (c) certain gram-positive 
organisms such as Methicillin Resistant Staphylococcus epidermidis (MRSE) and Group D 
Streptococcus, 2) Because single-stage revision requires that the implant be inserted with 
antibiotic loaded cement, patients with significant bone stock deficiency cannot be managed 
with this technique 3) Lack of data on the use of bone graft in association with single-stage 
revision 4) Difficulties with removal of a solidly fixed cemented prosthesis without 
destroying the remaining proximal femoral bone stock should the procedure fail to eradicate 
the infection. Nevertheless, single-stage revision remains a viable option which is associated 
with less morbidity and is less expensive than delayed exchange when used in carefully 
selected patients. 
1.7.2.2 Two-stage Revision 
Two-stage reimplantation is the gold standard for the treatment of infected joint arthroplasties 
today as the successful eradication of a TJA infection is over 90% (Lin et al., 2001). 
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Furthermore, it permits uncemented reconstruction and the use of allografts which is 
particularly important given the frequency of femoral and acetabular defects associated with 
THA infections (Berry et al., 1991, Haddad et al., 2000b, Lai et al., 1996). Alexeeff (Alexeeff 
et al., 1996) used massive structural allografts in the second stage of a two-stage procedure in 
11 patients. They reported no additional sepsis at a mean follow-up of 4 years. The principles 
of a two-stage revision include removal of the implant along with all cement and necrotic 
tissue which contain infectious organisms, administration of systemic antibiotics 
postoperatively for 6 to 12 weeks and eventual implantation of a new prosthesis. A patient is 
deemed free of infection and able to proceed to second-stage arthroplasty when repeat joint 
aspirates after discontinuing antibiotics are negative, and blood parameters return to normal 
values. Placement of antibiotic loaded cement in the form of spacers during the intervening 
treatment period to deliver antibiotics locally has been popularised due to the even higher 
rates of eradicating infection achieving up to 95% in several studies (Hofmann et al., 2005, 
Younger et al., 1997). This system increases local antibiotic levels up to 200 times higher 
than those
 
for systemic administration whilst preventing debris from accumulating
 
in the 
potential joint space and soft-tissue contractures (Masri et al., 1998). When used in temporary 
spacers, antibiotic dosages up to 20 g per 40 g of bone cement have been reported without 
systemic side effects (Springer et al., 2004). For fungal infections, 100 to 150 mg of 
amphotericin B is typically added to the 40 g of bone cement in addition to other antibiotics 
chosen. However, when used for prophylaxis in single-stage revisions, a maximum dose of 2 
grams per 40 grams mix is recommended to avoid weakening the mechanical properties of 
the cement. Such dose has shown a level of activity that passed for more than eighty days the 
level of minimum inhibitory concentration (MIC) of the most common pathogens (Stevens et 
al., 2005). It is also worth noting that the additive or synergistic effect of combining 
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antibiotics in the cement has been studied and showed improved efficacy and less resistance 
to the antibiotics used (Bertazzoni Minelli et al., 2004, Gonzalez Della Valle et al., 2001). 
1.7.2.3 Spacers 
Spacers are classified as static or non-articulating spacers, medullary dowels, and articulating 
or mobile spacers. Although antibiotic loaded cement beads have also been used previously, 
they are rarely advocated nowadays in the treatment of the infected joint arthroplasty due to 
the associated scarring and as a result, the difficulty in identifying and removing them at the 
second stage procedure (Taggart et al., 2002). Types of spacers include the following: 
a) Static/nonarticulating spacers: Static or simple block spacers aim at maintaining the dead 
space and are mostly used in the acetabulum. They facilitate surgical dissection at the 
time of reimplantation and allow delivery of the antibiotics of choice according to 
sensitivities. Typically, 20 g of bone cement mixed with at least 2 or 3 g of powdered 
antibiotic provides an adequate volume for the acetabular defect. The disadvantage of a 
static spacer is that it does not allow physiological motion of the joint, although this has 
been associated with less generation of debris in comparison with mobile spacers (Burnett 
et al., 2007, Stockley et al., 2008) 
b) Medullary dowels:  A tapered cement dowel fashioned from the nozzle of a cement gun 
provides an excellent size and shape for a spacer to be inserted into the medullary canal 
during treatment of infected THA. A small bulb is left at the end of the dowel to prevent 
migration of the dowel down the femoral canal and help facilitate removal. Disadvantages 
include the potential for proximal femoral migration and the inability of using them in 
patients with severe femoral bone loss (Burnett et al., 2007, Stockley et al., 2008). 
c) Mobile/articulating spacers (such as the PROSTALAC): The primary concept of this 
technique allows the patient to move the affected joint through a range of motion during 
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the time between prosthesis removal and insertion of the new prosthesis. The Prosthesis 
of Antibiotic Loaded Acrylic Cement (PROSTALAC) first developed by Duncan and 
Beauchamp (Duncan and Beauchamp, 1993) was composed of a metal femoral 
endoskeleton component covered
 
with antibiotic loaded cement. The cement of the 
femoral head
 
articulated with the bone of the acetabular bed, which could unfortunately
 
lead to bone erosion and discomfort. An acetabular cement component
 
was therefore 
introduced; preventing loss of acetabular bone, but the cement-on-cement articulation 
limited motion and
 
caused discomfort. The PROSTALAC system now consists of a 
constrained cemented acetabular component with an articulating polyethylene liner and a 
femoral component with a modular head that is made intra-operatively with antibiotic 
loaded cement surrounding a stainless steel endoskeleton, using a series of molds. Whilst 
providing high doses of local antibiotic delivery, this system also allows earlier 
mobilisation out of bed and accelerated rehabilitation and discharge from the hospital 
between stages of treatment avoiding the complications associated with prolonged 
hospital stay and immobilisation (Haddad et al., 1999). More recently, the option to use a 
preformed PROSTALAC equivalent with fixed low-dose antibiotic content has become 
available. Prefabricated molds of different sizes are also now available, allowing the 
surgeon to select antibiotic dose and content. However, the disadvantages of preformed 
mobile spacers include limitation in implant sizes and antibiotic dose, often allowing 
delivery of only a single antibiotic. Mobile spacers formed in the operating room have the 
advantage of adjustable antibiotic dosing; a combination of antibiotics and the addition of 
an antifungal option as necessary. Disadvantages of mobile spacers formed in the 
operating room though include additional time to construct the implant, a limited number 
of sizes, additional cost, and complications may similarly occur. 
Complications of spacers: 
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a) Implant and periprosthetic fractures: Surgeon made spacers in the operating room may be 
at higher risk for a fracture, especially with a mobile spacer, as a result of cement 
heterogeneity and inconsistencies in mixing. The use of higher antibiotic doses also leads 
to increased risk of fracture. A noncongruent femoral component fit on host femoral bone 
may lead to subsidence and fracture of the implant. Therefore, the surgeon should avoid 
impacting the mobile cement spacer during cementing which may predispose both the 
prosthesis and the bone stock deficient proximal femur to fracture (Burnett et al., 2007). 
b) Antibiotic toxicity: A rare complication which may occur more frequently with surgeon 
constructed spacer implants when high doses of antibiotics are added to the cement 
(Masri et al., 1998). Patient factors which may potentiate antibiotic toxicity include renal 
failure. Therefore, renal function and antibiotic levels monitoring is crucial in this group 
of patients and should this complication occur, removal of the implant must be 
considered.  
c) Instability: This occurs more frequently with knee spacers. However, in the hip, the use of 
a snap-fit polyethylene liner has reduced the incidence of this complication (Burnett et al., 
2007). 
Two-stage revision arthroplasty using antibiotic loaded cement but without a prolonged 
course of antibiotic therapy has also been reported by Stockley (Stockley et al., 2008) in a 
series of 114 patients for chronic THA infections. Infection was successfully eradicated in 
100 patients (87.7%) at a mean follow-up of two years.  
1.7.2.4 Multi-stage Revision  
A three-stage reimplantation procedure is suitable for treatment of extensive bone defects in 
which the use of a large amount of morselised allograft can be anticipated. The bone bed 
created is allowed to incorporate for about 6 months and, in most cases, a cementless implant 
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is subsequently inserted (Landor et al., 2005). Multi-stage revision is also indicated when 
clinical presentation, blood parameters and cultures are suggestive of persistent infection 
requiring further debridement and possible repeat of PROSTALAC to eradicate infection 
after the first stage of revision. 
1.7.3 Salvage Procedures 
1.7.3.1 Long Term Suppressive Antibiotics  
Chronic suppressive therapy for periprosthetic infections is indicated when an operation is 
refused by the patient or is believed to be associated with an unacceptable risk in medically 
unfit patients (Goulet et al., 1988). Infection is suppressed rather than eradicated with this 
type of treatment. The infecting organism must be identified and sensitive to the chosen 
antibiotic which should be effective orally and tolerable by the patient. Failures of treatment 
are due to the patient developing side effects like diarrhoea or recurrent candidiasis and the 
emergence of resistant strains.  
1.7.3.2 Excision Arthroplasty 
In life threatening or intractable hip or knee infections, an excision arthroplasty should be 
considered. Other indications for an excision arthroplasty include the elderly patient who is 
not capable of mobilising independently, those who are mentally impaired and may be unable 
to cooperate with the postoperative rehabilitation process, uncooperative patients such as 
intravenous drug abusers and the immunocompromised patients (Haddad et al., 1999). 
Excision arthroplasty is primarily aimed at pain relief and eradication of infection. However, 
such patients must be warned to expect at least 2-3cm of limb shortening and reliance upon a 
walking aid postoperatively (Sharma et al., 2005). The greater the bone loss, the more 
unsatisfactory an excision arthroplasty becomes. 
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1.7.3.3 Arthrodesis  
Arthrodesis is an alternative treatment in PJI and has been described by Kostuik (Kostuik and 
Alexander, 1984) a series of 14 patients where the indications were young age, male gender 
and strenuous functional demands. Although all hips eventually fused and patients were able 
to mobilise independently, patients had an average of 4.6cm limb-length discrepancy.    
1.7.3.4 Amputation  
Amputation is rare and generally reserved for patients with life threatening infections, 
multiple unsuccessful revisions and vascular injuries. 
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An RCT of Triclosan Coated versus 
Uncoated Sutures in Primary Hip and 
Knee Arthroplasty 
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2.1 Introduction 
Total hip and total knee arthroplasties are among the commonest operations in orthopaedic 
practice. The thirteenth annual report of the National Joint Registry (NJR, 2016) showed that 
around 796,000 THAs and 870,000 TKAs were performed in England and Wales between 1 
April 2003 and 31 December 2015. 
Although infection after hip and knee arthroplasties may be caused by haematogenous 
seeding, it is more commonly due to bacteria entering the wound at the time of surgery 
(Sukeik and Haddad, October 2009). Various bacteria may contaminate not only the tissue in 
the surgical wound but the suture material (Uff et al., 1995, Rodeheaver et al., 1983). To 
prevent microbial colonisation of suture material in operative wounds, the coated Vicryl Plus 
triclosan (polyglactin 910) suture (Ethicon, Inc.) was developed and approved by the Food 
and Drug Administration in 2002. Triclosan is a broad-spectrum antiseptic which has been 
widely used in humans for more than 30 years (Barbolt, 2002) and is effective against 
Staphylococcus aureus and Staphylococcus epidermidis including methicillin-resistant 
strains, vancomycin-resistant Enterococcus faecalis, Pseudomonas aeruginosa, and 
Escherichia coli (Edmiston et al., 2006, Rothenburger et al., 2002). Vicryl Plus sutures (VPS) 
which are impregnated in triclosan have recently been shown to reduce bacterial adherence to 
sutures and reduce microbial viability both in vitro and in animal models (Edmiston et al., 
2006, Gomez-Alonso et al., 2007, Rothenburger et al., 2002, Storch et al., 2002a, Storch et 
al., 2002b) with a high safety margin, little or no risk of allergic reactions and no evidence of 
microbial resistance (Barbolt, 2002, Gilbert and McBain, 2002). In human subjects, evidence 
has consistently been in favour of VPS in relation to cost and safety profile. Its effect on 
wound healing and infection rates has also been investigated with positive findings in all of 
the meta-analyses conducted despite most of the evidence coming from abdominal surgery 
(Apisarnthanarak et al., 2015, Daoud et al., 2014, Guo et al., 2016, Wang et al., 2013). A 
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number of trials have also suggested a positive effect of triclosan coated sutures (Nakamura 
et al., 2013, Thimour-Bergstrom et al., 2013). For example, Ford (Ford et al., 2005) reported 
in an RCT, which included 147 paediatric patients who underwent general surgical 
procedures, that VPS decreased postoperative pain, with overall comparable wound handling 
parameters, when compared to standard vicryl sutures. Justinger (Justinger et al., 2009) used 
the VPS for abdominal wall closure in >2,000 patients in a prospective study, concluding that 
using it decreased the rates of wound infections after a midline laparotomy from 10.8% to 
4.9% (P<0.001). In an RCT of 856 patients, Justinger (Justinger et al., 2013) showed 
that triclosan impregnation of a 2-0 polydioxanone closing suture can decrease wound 
infections in patients having a laparotomy for general and abdominal vascular procedures. 
Similarly, Rozzelle (Rozzelle et al., 2008) conducted an RCT on 84 patients, comparing 
infection rates in cerebrospinal-fluid shunt-implantation wound closure, using VPS or 
standard vicryl sutures. The results were again in favour of the VPS, with an infection rate of 
4.3% versus 21% in the control group. Fleck (Fleck et al., 2007) conducted a retrospective 
study on 479 cardiac patients undergoing sternal wound closure, using the two types of 
sutures, and found that all 28 patients who developed infection were in the standard wound 
closure group. Mingmalairak (Mingmalairak et al., 2009) conducted an RCT comparing the 
two types of sutures in patients undergoing appendicectomy, the preliminary report of 100 
patients showed no significant difference in surgical site infection (SSI) rates, with the 
authors further concluding that the use of VPS is safe and satisfactory in surgical practice.  
In the National Health Service (NHS), there has been a recent shift in practice in many 
hospitals whereby VPS has become the suture of choice for wound closures in different 
surgical specialties including Orthopaedics assuming that benefits outweigh any 
disadvantages. In Orthopaedics however, no trials to date have investigated the benefits of 
using VPS for wound closures.  
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We therefore hypothesised that VPS will be associated with better wound healing 
characteristics compared to the vicryl sutures, and as a result may potentially be more 
appropriate for total hip and total knee arthroplasty wound closures. 
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2.2 Patients and Methods 
A single-centred, double-blind RCT has been conducted to compare the healing 
characteristics of wounds closed using VPS and standard vicryl sutures in patients 
undergoing primary total hip or total knee arthroplasty. The protocol for the study was 
approved by the local Research and Development (R&D) department and Regional Ethics 
Committee (REC) and written informed consent was obtained from all patients.  
2.2.1 Patient Selection Criteria 
Patients listed for a primary hip or knee arthroplasty under the care of one surgical team at 
University College London Hospital (UCLH) constituted the study groups for the trial.  
a) Inclusion criteria: 
Adult patients (age≥18 years) undergoing unilateral primary total hip or knee 
arthroplasty 
b) Exclusion criteria: 
1) Unilateral primary total hip or knee arthroplasty performed for trauma  
2) Revision procedure or a previous incision in the operative field  
3) History of tendency for keloid formation 
4) Allergy to triclosan/vicryl 
5) Bleeding tendency (e.g. haemophilia and platelet disorders) or being on regular 
anticoagulation treatment (e.g. warfarin, treatment dose of low molecular weight 
heparin (LMWH) or conventional heparin) 
6) Underlying malignancy and immunocompromised status  
7) Dementia and mental illnesses preventing informed consent 
8) Children (age<18years) 
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Permitted therapies included: 
1. Aspirin 
2. Subcutaneous prophylactic conventional or LMWH  
 
2.2.2 Patient Recruitment 
Patients were approached to participate in the trial at the pre-assessment clinic 3 weeks before 
their operation by a member of the research team who attended the clinic. The trial was 
discussed with them and the written information sheet supplied (Appendix 2.1). Contact 
numbers of the research team were provided if patients wanted to discuss any issues before 
they participated in the trial. On admission, patients were given the opportunity to ask any 
further questions and were invited to sign the consent form (Appendix 2.2). Non English 
speakers were provided with translators. It was explained that there was no requirement to 
participate and that refusal would not prejudice continued care in any way. The general 
practitioners of the recruited patients were informed by a postal letter (Appendix 2.3). 
2.2.3 Trial interventions 
Participants were randomly assigned to receive coated polyglactin 910 sutures with triclosan 
(Vicryl Plus; Ethicon, Inc.) or conventional sutures (coated polyglactin 910 – Vicryl; Ethicon, 
Inc.). The operations were performed according to the senior surgeon’s (FSH) default 
procedures which include using a medial parapatellar approach and cemented TKAs and a 
posterior approach and uncemented THA prostheses. Closure of the TKA wounds included 
using interrupted 1 vicryl/VPS for the medial parapatellar incisions and 2-0 vicryl/VPS for 
the subcutaneous tissues followed by skin clips. Closure for the THA wounds included using 
interrupted 1 vicryl/VPS for the fascia lata and 2-0 vicryl/VPS for the subcutaneous tissues 
followed by skin clips. For TKAs, a tourniquet was only inflated at the time of cementation 
and was released after dressing the wound. No drains were used. Antibiotic prophylaxis 
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included 3 doses of intravenous cefuroxime 750mg or alternatively 2 doses of teicoplanin 
400mg if the patient was allergic to cefuroxime, with the first dose given at induction of 
anaesthesia and the rest within the first 24 hours from the operation. All patients received 
anti-embolism stockings as well as LMWH for thromboprophylaxis. Perioperative care plans 
were similar for each type of operation. 
2.2.4 Randomisation and blinding 
Randomisation and blinding were performed by SealedEnvelope Ltd. with assignment of 
letter codes to study and control groups. The suture type corresponding to a particular letter 
code was known only to the member of team who received the codes and was not part of the 
operating surgeons as well as the operating room nurses. An equal number of study and 
placebo letter code cards were prepared and placed individually in sealed envelopes. The 
nurses used consecutive allocation which was concealed from all professionals delivering 
patient care. Participants and investigators were blinded to treatment assignment (double-
blinded study), because study and placebo sutures are indistinguishable after removal of the 
package labelling by the nurses. 
Block randomisation was used, with unequal block sizes in order to keep the sizes of 
treatment groups similar. The randomisation schedule was performed by SealedEnvelope Ltd. 
Randomisation codes were only broken in a case of a serious adverse event according to 
SealedEnvelope Ltd. protocol of unblinding as detailed in the data monitoring section. 
2.2.5 Outcome Measures 
a) Primary outcome: 
The primary outcome was the ASEPSIS wound scoring system devised by Professor 
Wilson in 1986 at UCLH (Wilson et al., 1986). ASEPSIS is a quantitative wound 
scoring method and is calculated using objective criteria based both on visual 
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characteristics of the wound and the consequences of infection (Tables 2.1 and 2.2). A 
score of > 10 indicates an increasing probability and severity of infection (Table 2.3). 
The ASEPSIS scoring system has been shown to be both objective and repeatable 
(Wilson et al., 1986, Bruce et al., 2001, Wilson et al., 2004). The reason for choosing 
the ASEPSIS scoring system was to analyse the wound healing characteristics for the 
sutures included in the study with an assessment of infection risk as a higher 
ASEPSIS score is indicative of various severities of an infection.  
Criterion        Points 
Additional treatment 
 Antibiotics       10 
 Drainage of pus under local anaesthetic   5 
 Debridement of wound under general anaesthetic  10 
Serous discharge       0 to 5 
Erythema        0 to 5 
Purulent exudate       0 to 10 
Separation of deep tissues      0 to 10 
Isolation of bacteria       10 
Stay in hospital over 14 days      5 
  
 
Table 2.2 Points scale for ASEPSIS daily wound inspection 
     Proportion of wound affected (%) 
  0   > 0 to19  20 to 39  40 to 59  60 to 79  80 to 100 
Serous  0  1   2   3   4   5 
exudate    
Erythema  0  1   2   3  4   5 
Purulent 0 2   4   6   8   10 
exudates  
Separation of 0  2   4   6   8   10 
deep tissues  
Table 2.1 Points scale used to calculate total ASEPSIS score 
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Score   Meaning 
0 to10   No infection 
  Normal healing 
11 to 20  Disturbance of healing 
21 to 30  Minor infection 
31 to 40  Moderate infection 
≥ 41   Severe infection 
 
b) Secondary Outcomes: 
 Time for wound closure: Defined as the time period in minutes after insertion of the 
prosthesis and commencing closure of the fascia in case of THAs or retinaculum for 
TKAs until completion of skin clips insertion. 
 Length of operation in minutes 
 Length of hospital stay in days  
 Pain assessment using the visual analogue scale scores (1-10) measured at 1, 3 and 5 
days postoperatively. 
 Complications (see section on adverse events) 
 
2.2.6 Data Processing 
Research team members (MS, DG, AG and RK), collected the data and stored it on a 
modified Excel 97 database in accordance with the data protection act using a password 
protected computer in a locked office. The data was only accessible to members of the 
clinical care team and all records are being stored for 20 years in a locked file storing cabinet. 
A data collection form has been devised (Appendix 2.4). Data collected on the form include: 
1) ASEPSIS scoring: 
Table 2.3 Breakdown of ASEPSIS scores 
 59 
 
Wounds have been assessed by a member of a specialist team, made up of a nurse and 
three healthcare assistants. The sole role of this team was to collect and record data on 
wound healing according to ASEPSIS and all members had already received 
specialist training in the different definitions and diagnosis of surgical site infection. 
They were blinded to the type of suture used. Microbiology tests, such as wound 
swabs or tissue cultures, were performed according to clinical judgement. No specific 
microbiology tests were requested for the study purposes alone. Surgical wounds were 
inspected two or three days after the operation and again on days four or five if the 
patient was still in hospital. The proportion of each wound exhibiting erythema, 
serous discharge, purulent discharge or dehiscence have been recorded. At each post-
operative visit, the notes and drug charts of each patient were inspected. The 
diagnosis of a wound infection by a medical practitioner, the prescription of 
prophylactic or therapeutic antibiotics and the opening of a wound or drainage of an 
abscess were recorded. Raised WBC and inflammatory markers are common after 
THA and TKA. Microbiology swabs can be contaminated and can be inconclusive. 
At the time of discharge patients were given a simple ‘yes/no’ questionnaire regarding 
their wound, which they have been asked to complete and return in a pre-paid 
envelope two months later. Patients were contacted by telephone if no postal 
questionnaire was returned. The questionnaire was used to ascertain whether a wound 
infection had been diagnosed since discharge, whether antibiotics had been prescribed 
for the wound, whether any further surgery had been necessary and whether the 
hospital stay had been longer than 14 days. Additionally, each patient attended our 
arthroplasty clinic at UCLH at 2 and 6 weeks postoperatively for assessment of the 
wound and any additional treatment necessary. A single patient episode was defined 
as an operation with follow-up of either 2 months or until a further operation is 
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performed, whichever is shorter. At any time point, surgical site infection resulting in 
readmission was recorded in the database. 
2) Patients’ demographics, risk factors affecting wound healing, surgical data and 
postoperative complications:  
These were collected for baseline comparison of the study groups through attendance 
of pre-assessment clinics, operative lists and follow-up clinic appointments. Risk 
factors affecting wound healing included operative time and patient age, gender, body 
mass index, diabetes, smoking and performance level classified according to the ASA 
grade (Keats, 1978). 
2.2.7 Statistical Analysis and Data Monitoring 
PR, Senior Research Associate, Biostatistics group, Joint University College London/Royal 
Free Biomedical Research Unit, was involved in the design of the study and carried out the 
sample size calculation in Stata 11. MS analysed the results in SPSS 21. 
Data from 319 patients who had received the standard vicryl suture was available. These 
patients had an ASEPSIS score ranging from 0 to 33. A clinically significant difference as 
discussed with Professor Wilson who devised the ASEPSIS scoring system would be the 
VPS reducing the ASEPSIS score by 10 as this is equivalent to reducing the scores by a 
category (i.e. moderate to minor infection).  If the VPS reduced all patients with a score of 11 
to 20 to 10 and below and everyone else to a score 10 lower, then we would expect 97.5% of 
patients to score 10 and below. Sample size calculations were performed under the following 
assumptions: a two group RCT with equal group sizes, 90% of patients on the standard vicryl 
suture to have a score of ten and below and 97.5% of patients with the VPS to have a score of 
10 and below, two sided 5% significance, 80% power, and 10% dropout. 210 patients are 
required in each group. We anticipated recruitment over 24 months. 
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Recruitment and progress through the study has been summarised using a Consort diagram as 
detailed in the Results section. The two study groups’ baseline characteristics were compared 
using means and standard deviations for continuous data and frequency counts and 
percentages for categorical data. The primary outcome which is the binary variable ASEPSIS 
score ten and below versus score 11 and over has been analysed with a chi-squared test for a 
2x2 contingency table. If the two study groups were not comparable then the primary 
outcome was further analysed with logistic regression including the baseline characteristics 
as co-variates. The primary outcome score was also analysed with the Mann-Whitney U test 
as a secondary sensitivity analysis. Continuous secondary outcomes such as time for wound 
closure, length of operation and hospital stay were analysed with the Mann-Whitney U test. 
Categorical secondary outcomes such as postoperative complications were analysed with the 
Fisher exact test. The proportion of dropouts from the study and adverse events were 
reported. Data analysis was done on an intention to treat basis. All statistical analyses were 
performed with SPSS version 21.0 software (SPSS, Inc.). Randomisation codes were broken 
only in the case of a serious adverse event and this was documented and discussed with the 
data monitoring committee and sponsor according to the unblinding protocols set up by 
SealedEnvelope Ltd. without discontinuing the trial. The data monitoring committee included 
Professor Wilson and members of his team who were not directly involved in conducting the 
study. 
2.2.8 Withdrawal from the trial 
All patients were permitted to withdraw from the study at any point without prejudice to the 
routine care available. 
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2.2.9 Safety profile 
Adverse Reaction (AR): Means any untoward and unintended response in a participant to the 
VPS as stated in the Summary of Product Characteristics (SmPC). 
Adverse reactions associated with the use of this device include: 
1. Wound dehiscence 
2. Minimal acute inflammatory tissue reaction 
3. Localised irritation 
4. Suture extrusion and delayed absorption in tissue with poor blood supply 
5. Allergic reaction to triclosan  
6. Calculi formation in biliary and urinary tracts when prolonged contact with salt 
solutions such as bile and urine occurs 
Adverse Event (AE): Any untoward medical occurrence in a participant to whom the study 
drug has been administered and which does not necessarily have a causal relationship with 
this treatment. These include the complications of THA and TKA as well as ARs mentioned 
above. The followings have been reported as potential complications: 
1. Nausea and Vomiting 
2. Dizziness 
3. Pain (acute and chronic) 
4. Bleeding 
5. Stiffness 
6. Neurovascular injuries 
7. Deep venous thrombosis 
8. Chest infection 
9. Pulmonary embolism 
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10. Myocardial infarction 
11. Cerebrovascular accidents 
12. Infection 
13. Fracture 
14. Dislocation 
15. Loosening of the prosthesis 
16. Death 
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR): Means any of the above 
AEs or ARs respectively that:  
1. results in death; or 
2. is life threatening; 
3. requires hospitalisation or prolongation of existing hospitalisation; 
4. results in a persistent or significant disability or incapacity 
5. consists of a congenital anomaly or birth defect in offspring of subjects or their 
partners taking the study drug regardless of time of diagnosis 
6.  Important medical events that may not result in death, be life threatening, or require 
hospitalisation may be considered serious adverse events when, based on appropriate 
medical judgement, they may jeopardise the patient and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include acute renal failure, allergic bronchospasm 
requiring intensive treatment or blood dyscrasias. 
Suspected Serious Adverse Reaction (SSAR): means one of the above mentioned adverse 
reactions of the VPS that is classed in nature as serious which is consistent with the 
information about the medicinal product listed in the relevant reference documentation 
(SmPC). 
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Unexpected Adverse Reaction: An adverse reaction, the nature or severity of which is not 
consistent with the applicable product information. 
Suspected Unexpected Serious Adverse Reaction (SUSAR): means an adverse reaction that is 
classed in nature as serious and which is not consistent with the information about the VPS. 
Other Safety Issues considered to be Serious: Other safety issues where they might materially 
alter the current benefit-risk assessment of the medical device or that would be sufficient to 
consider changes in the medical device administration or in the overall conduct of the trial 
also need to be considered serious, for instance: 
a. an increase in the rate of occurrence or a qualitative change of an expected serious 
adverse reaction, which is judged to be clinically important, 
b. post-study SUSARs that occur after the patient has completed a clinical trial and are 
reported by the investigator to the Sponsor, 
c. new events related to the conduct of the trial or the development of the medical device  
and likely to affect the safety of the subjects, such as: 
 an SAE which could be associated with the trial procedures and which could 
modify the conduct of the trial, 
 a significant hazard to the subject population such as lack of efficacy of a medical 
device used for the treatment of a life-threatening disease, 
 any anticipated end or temporally halt of a trial for safety reasons and conducted 
with the same investigational medicinal products in another country by the same 
Sponsor, 
d. recommendations of the Data Monitoring Committee, if any, where relevant to the safety 
of the subjects. 
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2.2.10 Adverse Events / Reactions Monitoring 
The occurrence of serious and non serious AEs and ARs in patients on both trial arms was 
sought while they were in hospital and at each subsequent hospital visit. Patients were asked 
about hospitalisations, consultations with other medical practitioners, disabilities or 
incapacity and whether any other adverse events have occurred.  
A section in the data collection sheet has been designed to record SAEs as defined above in 
the complications section. SAEs have been assessed and recorded in the patient’s medical 
notes including the start dates (if known) of the onset of the event as well as the date the 
event stopped or changed, treatment and outcome; if applicable. 
2.2.11 Adverse Events / Reactions Reporting 
 Non serious adverse events have not been reported. These are quite common and 
mostly self limiting in the first few days after surgery.  
 Serious adverse events: SAEs have been reported to the principal/chief investigator 
within 24 hours and evaluated for seriousness, expectedness and severity by them. If 
there was a significant increase in the incidence of the above SAEs above the reported 
incidence, the sponsor would have been informed and consulted. The causality of 
SAE would have been evaluated by the data monitoring committee as above and if 
causality of these SAEs was linked to the VPS, it would have been reported to the 
Medicines and Healthcare products Regulatory Agency (MHRA), REC within 7 days 
if the event was fatal or life threatening or 15 days if the event was not fatal or life 
threatening. 
 In accordance with the European Union directive (article 16 & 17) the principal/chief 
investigator would have reported SUSARs to the sponsor within 24 hours of 
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becoming aware of the event. The chief investigator and the sponsor would have 
reported SUSARs to the MHRA, REC within the required  reporting timelines. 
We would have provided the following information when reporting an SAE: 
1. Protocol identification (Centre number and patient unique identification number) 
2. Subject identification (Patient initials, date of birth, sex) 
3. The description of the SAE, intervention and the outcome 
4. Relevant medical background 
5. Any other available information that is requested by the MHRA, REC or the local 
R&D department 
 
2.2.12 Ethical Considerations 
MHRA was contacted and it has been ascertained that the trial did not come under the 
MHRA regulations as the suture is counted as a medical device, not a pharmaceutical drug. 
Informed consent has been obtained from patients. (Appendix 2.6) 
  
 67 
 
2.3 Results 
The trial was started in November 2013 after obtaining the necessary approvals from the 
UCLH Research and Development department (Appendix 2.7) and the Regional Ethics 
Committee (Appendix 2.8). It was registered with an International Standard Randomised 
Controlled Trial Number (ISRCTN) 21430045. 
 
2.3.1 Recruitment and Consort Flow Diagram  
Patients were recruited between November 2013 and December 2014. During this period, 
there were 320 patients scheduled for primary hip and knee replacements. However, 130 
patients were not approached at admission due to the non availability of the designated 
research staff to conduct the study. Fourteen patients were excluded for various reasons such 
as history of previous trauma accounting for the osteoarthritis, revision surgery or being on 
warfarin. Twenty six patients refused to take part in the study. Therefore the study consisted 
of 150 participants, 81 were randomised to the VPS and 61 were randomised to the standard 
vicryl suture (Figure 2.1). After December 2014, the hospital terminated the contract with 
Ethicon to move to another supplier and hence the sutures were no more available and the 
trial had to be ended and results analysed. 
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Figure 2.1 Consort Diagram of Patients’ Recruitment and Allocation 
 
2.3.2 Characteristics of the Study Population 
A total of 150 patients were analysed, 81 in the VPS and 69 in the standard group. The mean 
age was 68 years (SD 10.4). There were 49 males and 101 females and the primary indication 
for an operation was osteoarthritis in 145 (96%) patients. Although the numbers of cases was 
planned to be equal, the early termination of the study resulted in unequal numbers in each 
study group. There were 96 THAs and 54 TKAs performed and the mean length of hospital 
stay was 6.19 days (SD 4.15). One hundred and forty four patients (96%) completed the 
follow-up by either attending the 6 weeks outpatient appointment or sending in the post 
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VPS 
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suture  
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discharge questionnaire. Demographics and risk factors for wound complications and 
infection were comparable for the two groups (Table 2.4). 
 
Table 2.4 Patients demographics 
 Suture Statistical 
significance 
(p-value) 
Standard 
(n=69) 
VPS 
(n=81) 
Age Mean (SD) 67.85 (9.85) 68.65 (10.90) 0.44 
Diagnosis OA 
SUFE 
AVN 
Hip dysplasia 
Perthes 
68 
0 
1 
0 
0 
77 
2 
0 
1 
1 
0.33 
Gender Male 
Female 
24 
45 
25 
56 
0.73 
BMI Mean (SD) 28.70 (5.13) 29.14 (4.97) 0.54 
Smoker Yes 
Never 
Ex-Smoker 
6 
42 
13 
6 
57 
12 
0.64 
Diabetic Yes 
No 
4 
57 
10 
64 
0.26 
ASA Grade 1 
2 
3 
9 
47 
13 
9 
52 
20 
0.68 
OA: Osteoarthritis, SUFE: Slipped upper femoral epiphysis, AVN: Avascular necrosis, BMI: 
Body mass index, ASA: American Society of Anesthesiologist 
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2.3.3 Operative Data 
There were 96 THAs and 54 TKAs performed during the study. However, the procedures 
were balanced between the 2 arms of the trial (P =0.5). A Synergy-R3, Smith & Nephew and 
Trinity-TriFit TS, Corin were used for cementless THAs whereas in 3 cases a cemented 
Exeter was implanted as per surgeon’s preference. For TKAs, Triathlon, Stryker was used for 
the majority of cases and SAIPH
®
 Knee, MatOrtho® were used in some cases. The majority 
of the operations were performed by registrars (n=79) followed by the consultant (n=54) and 
then fellows (n=17) but again this was balanced between the 2 arms of the trial (P =0.63). 
The majority of patients underwent a general anaesthetic (95 patients). Cefuroxime was the 
prophylactic antibiotic used for most operations and teicoplanin was administered to 
penicillin allergic patients occasionally in combination with gentamicin. The length of 
operation was 91.24 minutes (SD 26.5) in the VPS group and 88.44 minutes (SD 23.84) in 
the standard vicryl group (P=0.67). An average of 4 sutures were used for wound closures in 
both groups and there was no significant difference in wound closure time between the study 
groups (VPS 13.89 (SD 5.13), standard vicryl 14.64 (SD 5.51), P=0.47). (Table 2.5) 
 
Table 2.5 Operative Data 
 Suture Statistical 
significance 
(p-value) 
Standard 
(n=69) 
VPS 
(n=81) 
Site Hip 
Knee 
42 
27 
54 
27 
0.5 
Surgeon Consultant 
Registrar 
Fellow 
25 
38 
6 
29 
41 
11 
0.63 
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Anaesthetic General 
Regional 
Both 
45 
17 
3 
50 
26 
2 
0.56 
Local anaesthetic Yes 
No 
67 
1 
77 
4 
0.38 
Antibiotic Cefuroxime 
Cefuroxime + Gent 
Teicoplanin + Gent 
Teicoplanin 
62 
0 
1 
3 
74 
1 
1 
2 
0.74 
Length of operation Mean (SD) 88.44 (23.84) 91.24 (26.5) 0.67 
Number of sutures used 
 
Mean (SD) 3.75 (0.87) 3.53 (0.81) 0.12 
2 
3 
4 
5 
>5 
1 
23 
30 
6 
1 
7 
29 
30 
8 
0 
0.26 
Prosthesis           Hip 
                             
 
                           Knee 
Synergy – R3 
Trifit – Trinity 
Exeter 
37 
3 
0 
48 
3 
3 
0.30 
Triathlon 
Saiph Knee 
21 
5 
23 
3 
0.70 
Wound closure (mins) Mean (SD) 14.64 (5.51) 13.89 (5.13) 0.47 
VAS Score  
(Mean, SD) 
Day 1 6.47 (2.62) 6.20 (2.35) 0.34 
Day 3 4.75 (2.33) 4.18 (2.33) 0.15 
Day 5 4.67 (1.75) 2.92 (2.87) 0.18 
Length of stay Mean (SD) 6.13 (4.23) 6.23 (4.11) 0.95 
Gent: Gentamicin, VAS: Visual analogue scale 
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2.3.4 Postoperative Outcomes 
2.3.4.1 Wound Outcomes 
Surgical wounds were scored using ASEPSIS two or three days after the operation and again 
on days four or five if the patient was still in hospital. The scores were further adjusted at the 
2 and 6 weeks follow up appointments and on receiving the post discharge questionnaire if 
any additional procedures were performed including the administration of antibiotics or 
drainage/washout of the wound. The binary variable ASEPSIS score ten and below versus 
score 11 and over has been analysed with a chi-squared test for a 2x2 contingency table and 
this showed no significant difference between the study groups as there were only 6 cases in 
the VPS group and 4 in the standard group who scored above 10 (P=0.75). However, the 
primary outcome score was also analysed with the Mann-Whitney U test as a secondary 
sensitivity analysis and this showed a significant difference in the scores among the study 
groups (VPS 2.54 vs. standard suture 1.41, P=0.036). Additionally, wound complications 
were also documented at the follow up appointments. At 2 weeks, there were 6 wound related 
complications in the VPS group including 2 superficial infections requiring antibiotics, a 
leaking wound and erythema surrounding the wounds in 3 cases whereas one case in the 
standard vicryl group needed oral antibiotics for a superficial infection (P=0.22). At 6 weeks, 
there were 8 wound related complications in the VPS group including 3 superficial infections 
requiring oral antibiotic treatment, one wound dehiscence, irritation from the suture in 2 
cases, persistent wound discharge in one case and deep wound infection requiring washout of 
the wound and exchange of the liner in a THA in one case. In the standard vicryl group, there 
was only one case which required oral antibiotics for a superficial wound infection at the 6 
weeks follow up appointment (P=0.03). (Tables 2.6, 2.7 and 2.8) 
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Table 2.6 ASEPSIS Scoring 
 Suture Statistical 
significance 
(p-value) 
Standard 
(n=69) 
Triclosan 
(n=81) 
ASEPSIS Scores for groups 0-10 
>10 
65 
4 
75 
6 
0.75 
ASEPSIS Scores Mean (SD) 1.41 (0.38-2.43) 2.54 (1.41-3.68) 0.036 
 
 
 
Table 2.7 Follow-up outcomes (2-week) 
 Suture Statistical 
significance 
(p-value) 
Standard 
(n=69) 
Triclosan 
(n=81) 
Attended follow-up Hospital 
Community 
Inpatient 
Did not attend 
35 
27 
2 
5 
37 
28 
10 
6 
0.21 
Wound complications Yes 
No 
1 
63 
6 
69 
0.22 
 
Superficial SSI 
Erythema 
Leaking wound 
1 
0 
0 
2 
3 
1 
 
SSI: Superficial site infection  
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Table 2.8 Follow-up outcomes (6-week) 
 Suture Statistical 
significance 
(p-value) 
Standard 
(n=69) 
Triclosan 
(n=81) 
Attended hospital Yes 
No 
61 
8 
65 
16 
0.189 
Wound 
Complications 
Yes 
No  
1 
60 
8 
57 
0.03 
 Superficial SSI 
Wound dehiscence 
Irritation from suture 
Serous discharge from wound 
Deep SSI 
1 
0 
0 
0 
0 
3 
1 
2 
1 
1 
 
Complications 
Nausea and vomiting 0 2 0.12 
Dizziness 0 0 1 
Bleeding (not from wound) 1 2 0.26 
Stiffness 4 5 0.30 
Neurovascular injury 0 0 1 
DVT 1 0 0.18 
PE 0 1 0.19 
Chest infection 1 2 0.26 
MI 0 0 1 
CVA 0 0 1 
Fracture 0 2 0.12 
Dislocation 0 0 1 
Loosening 0 0 1 
Mortality 0 0 1 
Missing data 8 16  
SSI: Surgical site infection 
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As planned, the primary outcome was further analysed with logistic regression including the 
baseline characteristics as co-variates as well. However, this did not show any significant 
effects of the potential risk factors for wound healing neither in the linear or the multiple 
regression analysis models. (Table 2.9)  
 
Table 2.9 Regression Analysis of Risk Factors for Wound Complications 
 Regression Analysis 
 Linear  Multiple 
Age 0.28 0.552 
ASA 0.347 0.534 
BMI 0.508 0.162 
Diabetes 0.723 0.990 
Gender 0.689 0.842 
Length of Operation 0.124 0.182 
Number of Sutures 0.628 0.232 
Smoking 0.311 0.546 
Time for Wound Closure 0.597 0.142 
Type of Anaesthesia 0.092 0.394 
ASA: American Society of Anesthesiologist, BMI: Body mass index,  
 
2.3.4.2 Visual Analogue Scores and Length of Hospital Stay 
There were no differences in the visual analogue scores measured on days 1, 3 and 5 or the 
length of hospital stay which averaged 6.23 days in the VPS group and 6.13 days in the 
standard vicryl group (P=0.95). (Table 2.2) 
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2.3.4.3 Complications 
Systemic complications occurring in the VPS group included nausea and vomiting in 2 
patients, gastrointestinal bleeding in two patients who underwent an endoscopy to treat an 
underlying gastric and duodenal ulcers, stiffness of the operated joint in 5 cases which was 
treated conservatively, two chest infections treated with antibiotics, one pulmonary embolism 
treated with LMWH then warfarin, a calcar fracture treated intraoperatively and an 
undisplaced greater trochanteric fracture noted postoperatively which was treated 
conservatively with protected weightbearing. Complications in the standard vicryl group 
included a patient who had melaena secondary to a duodenal ulcer which resolved 
spontaneously, stiffness of the operated joint in 4 patients which was treated conservatively, 
one chest infection treated with antibiotics and one deep vein thrombosis treated with LMWH 
then warfarin (P=0.24). 
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2.4 Discussion 
Due to the popularity of the VPS assuming its superiority in preventing infections and wound 
complications, it has become widely used in various surgical specialties even when the 
evidence is lacking. Therefore, we conducted this RCT to compare the wound healing 
characteristics of VPS and standard vicryl sutures in primary THA and TKA surgery. Despite 
the premature termination of this study due to the unavailability of the sutures after December 
2014, the study findings were significant to reject our hypothesis that the VPS will be 
associated with better wound healing characteristics and fewer infections than standard vicryl 
sutures. Although the binary variable ASEPSIS score ten and below versus 11 and over was 
insignificant, this may be related to a type II error due to an underpowered study. However, 
sensitivity analysis using the Mann Whitney test (P=0.036) as well as assessment of the 
wound complications at the last follow up showed significantly higher wound complication 
rates in the VPS group (P=0.03). 
Although the majority of evidence in the literature supports the use of VPS in surgical wound 
closures, there have been some studies published recently which questioned its efficacy and 
higher complication rates. For example, Mattavelli (Mattavelli et al., 2015) conducted a 
multi-centred RCT including 281 patients on the effect of triclosan coated sutures on SSI 
after colorectal surgery. The rate of SSI was reported as 12.9% (18/140) in 
the triclosan group versus 10.6% (15/141) in the control group (odds ratio: 1.24; 95% 
confidence interval: 0.60-2.57; p=0.564). Additionally, the overall incision complication rate 
was 45.7% in the triclosan group vs. 38.3% in the control group (odds ratio: 1.36; 95% 
confidence interval: 0.84-2.18; p=0.208). Another multi-centered RCT (Diener et al., 2014) 
investigating the effectiveness of triclosan-coated PDS Plus versus uncoated PDS 
II sutures for prevention of SSI after abdominal wall closure in 1224 patients showed that 
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triclosan-coated PDS Plus did not reduce the occurrence of surgical site infection. Similarly, 
a beneficial effect of triclosan against Gram positive bacteria could not be confirmed in 
another RCT comparing wound infection rates after colon and rectal surgeries in 485 patients 
(Huszar et al., 2012). Deliaert (Deliaert et al., 2009) conducted an RCT on 26 patients 
undergoing bilateral breast reduction surgery to evaluate wound dehiscence rates. Wound 
dehiscence occurred in 16 cases among the triclosan breast versus seven cases only in the 
control breast (McNemar test p = 0.023). Another RCT (Seim et al., 2012) reporting on 
wound closures in the lower limb showed that triclosan-coated sutures do not reduce leg 
wound infections after coronary artery bypass grafting with an infection rate of 10.0% 
(16/160) in the VPS group and infection rate of 10.4% (17/163) in the standard vicryl group 
(P = 1.00). The discrepancy in the effect of triclosan coated sutures among studies which 
dealt with abdominal surgery may relate to the microorganisms that differ substantially in 
different populations according to alimentary habits and environmental conditions (Hold, 
2014, Power et al., 2014). Other causes proposed include study design such as type of suture, 
the use of interrupted versus continuous sutures, single-layer abdominal closure and skin 
closure. Although triclosan has been associated with low systemic toxicity in a number of 
studies, negative effects such as dermatitis, skin irritation, allergic reactions and haematomas 
have been described (Fiss et al., 2007, Mattavelli et al., 2015). In hip and knee replacement 
surgery where rates of SSI are low in comparison to abdominal surgery, such effects may 
become more important as encountered in our study. It is also noteworthy that resistance to 
triclosan and multidrug resistance have recently been linked to the increase in environmental 
microbial communities exposed to triclosan and that there are plans proposed to 
quantitatively define the conditions under which triclosan selects for multidrug resistance in 
the environment (Carey and McNamara, 2015).  
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There are several strengths of this RCT. First, we conducted a double blinded RCT according 
to strict inclusion and exclusion criteria to address the intervention of interest. Second, this is 
the first RCT with reported outcomes in the literature investigating the effect of VPS on THA 
and TKA wounds. Third, the results of this RCT were consistent with a negative effect of 
VPS on wound closures after hip and knee arthroplasties. 
Limitations of this study include the premature termination of the trial due to the 
unavailability of the sutures after December 2014 which may have predisposed to a type II 
error as previously outlined. The duration of follow up is also short but this reflects the 
protocol for wound surveillance according to the ASEPSIS scoring system which addresses 
acute infections only. A longer follow up would be necessary to monitor for late infections.  
2.5 Conclusion 
In summary, the VPS has not been associated with better wound healing characteristics or 
fewer infections than standard vicryl sutures. Had the VPS group experienced a positive 
effect on the wounds, a much larger trial would have been required to show a statistically 
significant difference in wound healing characteristics. However, this study provides a valid 
basis for further investigation in a larger RCT. 
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Chapter 3 
 
The Effect of Tranexamic Acid on 
Wound Healing in Primary Total Hip 
Arthroplasty: A Meta-analysis 
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3.1 Introduction 
THAs are associated with considerable blood loss and numerous studies have shown that 
allogeneic blood transfusion increases the risk of SSIs through the mechanism of 
immunomodulation (Bloch et al., 2013, Friedman et al., 2014). The rates of SSI and lower 
and upper respiratory tract infections were significantly increased after total hip or total knee 
arthroplasty in more than 12,000 patients receiving allogeneic blood transfusion compared 
with those receiving autologous blood transfusion or no blood transfusion (Friedman et al., 
2014). On the other hand, the role of autologous transfusion in the risk of developing SSI and 
PJIs remains inconclusive. Taken together, much effort should be exercised perioperatively to 
reduce the need for any type of blood product transfusion.  
A variety of blood-conserving techniques have been developed to decrease blood loss and 
postoperative transfusion rates including controlled hypotension, regional anaesthesia, 
intraoperative blood salvage, erythropoietin and antifibrinolytic agents (Rajesparan et al., 
2009, Cardone and Klein, 2009). Antifibrinolytics which include tranexamic acid (TXA), 
aprotinin and epsilon aminocaproic acid (EACA) utilise different mechanisms to inhibit the 
dissolution of blood clots. They have been successfully used to stop bleeding after dental 
extractions, tonsillectomies, prostate surgery, heavy menstrual bleeding, cardiac surgery and 
in patients with haemophilia. Numerous studies have also investigated their efficacy in 
reducing blood loss and transfusion requirements in THA with no extra risk. However, no 
studies to date have investigated the direct relationship between antifibrinolytics and wound 
complications including SSIs. 
TXA has gained significant popularity in reducing perioperative blood loss, particularly after 
the publication of the Bart’s study (Fergusson et al., 2008). It is cheaper and safer than 
aprotinin and much more potent than EACA with overall good penetration into major joints 
(Ellis et al., 2001, Good et al., 2003). 
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Therefore, the purpose of this systematic review and meta-analysis was to investigate the 
hypothesis that TXA may be associated with less wound complications including SSIs after 
primary THA. 
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3.2 Materials and Methods  
The methods for this study were based on the Cochrane methodology for conducting 
systematic reviews and meta-analyses (Higgins and Green). 
3.2.1 Study Selection Criteria 
3.2.1.1 Types of Studies 
RCTs and quasi-randomised controlled trials (for example, allocation by hospital number or 
date of birth) trials have been considered for this review.  
3.2.1.2 Types of Participants 
The participants were adults who underwent THA regardless of the type or size of prosthesis 
used.  
3.2.1.3 Types of Interventions  
The intervention considered was the administration of intravenous TXA. Studies involving 
the administration of TXA by oral, topical or intramuscular route or comparing those to the 
intravenous route were excluded. Only studies with a control group were considered. The 
control group received a placebo, another antifibrinolytic agent or no treatment.  
3.2.1.4 Types of Outcome Measures  
The primary outcome measure was: 
Wound complications including infections 
The secondary outcome measures were: 
1. Intraoperative, postoperative and total blood loss 
 84 
 
2. The proportion of patients who had allogeneic blood transfusion. Hence, studies 
where autologous blood was systematically re-infused to part or all of their patients 
were not included in measuring this outcome in order to decrease bias. 
3. The amount of blood units transfused per patient 
4. Functional hip outcome measures (e.g. Oxford hip score) 
5. General quality of life outcome measures (e.g. SF 12, SF 36 or EUROQOL) 
6. Complications such as: Deep venous thrombosis (DVT), pulmonary embolism (PE), 
any thrombosis, renal failure, reoperation due to bleeding, non-fatal myocardial 
infarction, stroke and death. 
3.2.2 Search Methods for Identification of Studies  
The following exploded MeSH terms have been used for the initial literature search: 
“Antifibrinolytics”, “Tranexamic acid”, “Cyklokapron”, “Aprotinin”, “Trasylol”, “Epsilon 
aminocaproic acid” and “Amicar”. The Medline search was then refined to clinical trials and 
RCTs in human adults. Results were cross checked with other databases, namely EMBASE, 
the Cochrane Controlled Trials Register, HealthSTAR and CINAHL, Google and Google 
scholar for trials of antifibrinolytics and THA published in any language from 1966 to April 
2016.  
The bibliographies of retrieved trials and other relevant publications, including reviews and 
meta-analyses, were cross-referenced for additional articles. The following websites were 
searched to identify unpublished and ongoing studies: Current Controlled Trials 
(www.controlled-trials.com); Centre Watch (www.centerwatch.com); Trials Central 
(www.trialscentral.org); The UK National Research Register 
(www.nres.nhs.uk/researchsummaries). Journal of Bone and Joint Surgery - British Volume 
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(now the Bone and Joint Journal) and American Volume (www.ejbjs.org), and the American 
Academy of Orthopaedic Surgeons (www.aaos.org) were searched manually. 
3.2.3 Data Collection and Analysis  
3.2.3.1 Selection of the Studies 
Two authors (MS&SA) independently applied the search strategy to select references from 
the aforementioned databases. The article titles and abstracts were reviewed independently. 
When there was a doubt, the full article was retrieved for further scrutiny. The two authors 
independently assessed each full study report to see if it met the review's inclusion criteria. 
Authors were contacted for more information and clarification of data as necessary. 
Disagreement was discussed with the senior authors (JM&FSH) and when no consensus was 
reached, the particular study was excluded. 
3.2.3.2 Assessment of Methodological Quality of Included Studies 
The review authors used a modification of the generic evaluation tool used by the Cochrane 
Bone, Joint and Muscle Trauma Group (Madhok et al., 2007) (Table 3.1). Two authors 
(MS&SA) assessed the methodological quality of each study. Disagreement was resolved by 
the senior authors (JM&FSH). The total quality assessment score (QAS) was reported for 
each study, however; it was not used to weight the studies in the meta-analysis. 
Table 3.1 Quality Assessment Items and Possible Scores  
A. Was the assigned treatment adequately concealed prior to allocation? 
 
2 = method did not allow disclosure of assignment 
1 = small but possible chance of disclosure of assignment or unclear 
0 = quasi-randomised or open list/tables 
B. Were the outcomes of participants who withdrew described and included in the analysis (intention 
to treat)? 
 
2 = withdrawals well described and accounted for in analysis 
1 = withdrawals described and analysis not possible 
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0 = no mention, inadequate mention, or obvious differences and no adjustment 
C. Were the outcome assessors blinded to treatment status? 
 
2 = effective action taken to blind assessors 
1 = small or moderate chance of unblinding of assessors 
0 = not mentioned or not possible 
D. Were the treatment and control group comparable at entry? (Likely confounders may be age, 
partial or total rupture, activity level, acute or chronic injury)  
 
2 = good comparability of groups, or confounding adjusted for in analysis 
1 = confounding small; mentioned but not adjusted for 
0 = large potential for confounding, or not discussed 
E. Were the participants blind to assignment status after allocation? 
 
2 = effective action taken to blind participants 
1 = small or moderate chance of unblinding of participants 
0 = not possible, or not mentioned (unless double-blind), or possible but not done 
F. Were the treatment providers blind to assignment status? 
 
2 = effective action taken to blind treatment providers 
1 = small or moderate chance of un blinding of treatment providers 
0 = not possible, or not mentioned (unless double-blind), or possible but not done 
G. Were care programmes, other than the trial options, identical? 
 
2 = care programmes clearly identical 
1 = clear but trivial differences 
0 = not mentioned or clear and important differences in care programmes 
H. Were the inclusion and exclusion criteria clearly defined? 
 
2= clearly defined 
1= inadequately defined 
0= not defined 
I. Were the interventions clearly defined? 
 
2 = clearly defined interventions are applied with a standardised protocol 
1 = clearly defined interventions are applied but the application protocol is not standardised 
0 = intervention and/or application protocol are poorly or not defined 
J. Were the outcome measures used clearly defined? (by outcome) 
 
2 = clearly defined 
1 = inadequately defined 
0 = not defined 
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K. Were diagnostic tests used in outcome assessment clinically useful? (by outcome)  
 
2 = optimal 
1 = adequate 
0 = not defined, not adequate 
L. Was the surveillance active, and of clinically appropriate duration? 
 
2 = active surveillance and appropriate duration 
1 = active surveillance, but inadequate duration 
0 = surveillance not active or not defined 
 
3.2.3.3 Data Extraction and Management 
A data extraction form was designed and agreed by the authors. A pilot test of five articles 
was performed to ensure the form's consistency. Initially, two authors (MS&SA) extracted 
the data independently which was later on reviewed jointly to produce agreed accurate data. 
Disagreements were resolved by consensus or consultation with the senior authors 
(JM&FSH). Authors of individual trials were contacted directly to provide further 
information when necessary. 
3.2.3.4 Statistical Analysis 
Review Manager Database (RevMan version 5.3, The Cochrane collaboration 2014) was 
used for analysis of the selected studies. Continuous data for each arm in a particular study 
was expressed as mean and standard deviation and the treatment effect as mean differences. 
Dichotomous data for each arm in a particular study was expressed as proportions or risks, 
and the treatment effect as risk differences. Missing data was sought from the authors. Where 
this was not possible or data was missing through loss to follow-up, intention-to-treat 
principles were used. 
Summary estimates of the overall effect of treatment are provided in the form of a forest plot. 
The Mantel-Haenszel (M-H) method was used to combine studies using a fixed effects 
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model. The presence of statistical heterogeneity was assessed through Q and I
2
 statistics, a 
value of I
2
 >50% being considered substantial heterogeneity. We planned to use funnel plots 
to assess reporting bias if more than 10 studies measured any particular outcome. We also 
compared the method descriptions of the included studies with the actual reported outcomes 
in the results section to assess selective outcome reporting bias. 
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3.3 Results 
3.3.1 Description of Studies  
The literature search strategy was applied, then refined and reapplied. Two hundred and thirty 
six studies were identified as potential relevant studies and subsequent scrutiny of the abstract 
led to the exclusion of 202 studies. Full publications were obtained for the rest of the studies. 
These were assessed and 13 further studies were excluded for various reasons according to 
inclusion and exclusion criteria. (Figure 3.1)  
Figure 3.1 PRISMA Chart of the Study Selection Process 
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Twenty one RCTs were included in the meta-analysis (Claeys et al., 2007, Ido et al., 2000, 
Niskanen and Korkala, 2005, Garneti and Field, 2004, Benoni et al., 2000, Benoni et al., 
2001, Ekback et al., 2000, Husted et al., 2003, Johansson et al., 2005, Lemay et al., 2004, 
Yamasaki et al., 2004, Barrachina et al., 2016, Hsu et al., 2015, Imai et al., 2012, Jaszczyk et 
al., 2015, Kazemi et al., 2010, Lee et al., 2013, McConnell et al., 2011, Oremus et al., 2014, 
Wang et al., 2016, Malhotra et al., 2010). (Table 3.2) 
 
Table 3.2: Characteristics of the Included Studies 
Study N Intervention Cementation 
DVT 
prophylaxis 
Anaesthesia 
Blood 
transfusion 
protocol 
QAS 
Barrachina 
2016 
 
72 
TXA 15 mg/kg before 
the operation and saline 
3 hours later 
Placebo (Saline) 
Uncemented LMWH Regional 
Hb < 85g/l 
(fit patient)  
Hb < 90g/l 
(elderly 
patient with 
comorbidity) 
24 
Barrachina 
2016 
 
71 
TXA 10 m/kg before 
the operation and 10 
mg/kg of TXA 3 hours 
later 
Placebo (Saline) 
Uncemented LMWH Regional 
Hb < 85g/l 
(fit patient)  
Hb < 90g/l 
(elderly 
patient with 
comorbidity) 
24 
Benoni 
2000 
39 
TXA 10 mg/kg at end 
of operation and 3 hrs 
later  
Placebo (Saline) 
Cemented LMWH 
Regional or 
General 
None 24 
Benoni 
2001 
40 
TXA 10mg/kg just 
before the operation  
Placebo (Saline) 
Cemented LMWH 
Regional or 
General 
None 24 
Claeys 
2007 
40 
TXA 10mg/kg 15 
minutes before 
operation 
Hybrid LMWH Regional 
Hb < 85 g/l 
or  
Hct< 27% 
23 
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Placebo (Saline) 
Ekback 
2000 
40 
TXA 10 mg/kg just 
before operation then 
1mg/kg/hr infusion 
over 10 hrs + 10mg/kg 
further dose after 3 hrs 
from operation 
Placebo (Saline) 
Cemented LMWH Regional Hct <27% 22 
Garneti 
2004   
50 
TXA 10mg/kg at 
induction of 
anaesthesia  
Placebo (Saline) 
Cemented 
Mechanical 
only 
Regional None 24 
Hsu 2015 60 
TXA 1 gram just before 
operation and 3 hours 
after operation 
Placebo: (Saline) 
Uncemented LMWH General 
Hb < 80g/l 
(fit patient)  
Hb 80-90g/l 
(elderly 
patient with 
comorbidity) 
24 
Husted 
2003 
40 
TXA 10 mg/kg just 
before operation then 
1mg/kg/hr infusion 
over 10 hrs  
Placebo (Saline) 
Uncemented or 
Hybrid 
LMWH Regional 
Reduction in 
Hb>25% and 
clinical 
symptoms 
24 
Ido 2000 40 
TXA 1 gram just before 
operation and 3 hours 
after operation 
Control: None 
Cemented None Unknown None 14 
Imai 2012 46 
TXA 1 gram before 
skin closure 
 
Control: None 
Uncemented 
 
LMWH+ 
mechanical 
General and 
epidural 
None 17 
Imai 2012 
42 
TXA 1 gram before 
skin closure and 6 
hours later 
 
Uncemented LMWH+ 
mechanical 
General and 
epidural 
None 17 
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Control: None 
Imai 2012 
47 
TXA 1 gram before 
surgery 
 
Control: None 
Uncemented LMWH+ 
mechanical 
General and 
epidural 
None 17 
Imai 2012 
48 
TXA 1 gram before 
surgery and 6 hours 
later 
 
Control: None 
Uncemented LMWH+ 
mechanical 
General and 
epidural 
None 17 
Jaszczyk 
2015 
 
124 
TXA 15mg/kg just 
before surgery 
Control: None 
Uncemented LMWH Regional None 17 
Johansson 
2005   
100 
TXA 15mg/kg just 
before surgery 
Placebo (Saline) 
Cemented LMWH Regional Hb < 90g/l 24 
Kazemi 
2010 
64 
TXA 15mg/kg just 
before surgery 
Placebo (Saline) 
Uncemented LMWH Regional None 23 
Lee 2013 68 
TXA 15 mg/kg just 
before operation then 
15mg/kg infusion until 
skin closure  
Placebo (Saline) 
Uncemented 
Not 
recorded 
General and 
epidural 
Hct < 30% 23 
Lemay 
2004  
40 
TXA 10 mg/kg just 
before operation then 
1mg/kg/hr infusion 
until wound closure 
Placebo (Saline) 
Cemented or 
uncemented 
LMWH+ 
mechanical 
Regional 
Hb < 70g/l 
(fit patient)  
Hb < 90g/l 
(elderly 
patient with 
comorbidity) 
22 
Malhotra 
2010 
50 
TXA 15mg/kg just 
before surgery 
Placebo (Saline) 
Uncemented 
LMWH+ 
mechanical 
Regional None 23 
McConnell 
2011 
44 
TXA 10mg/kg just 
before the operation  
Uncemented 
Aspirin + 
Mechanical 
General and 
epidural 
None 17 
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Placebo (Saline) 
Niskanen 
2005 
36 
TXA 10mg/kg just 
before the operation 
then 8 and 16 hours 
later 
Placebo (Saline) 
Cemented 
LMWH + 
mechanical 
Regional or 
General 
Hct 0.28-
0.30 
24 
Oremus 
2014 
42 
TXA 1 gram just before 
operation and 3 hours 
later 
Placebo: (Saline) 
Uncemented LMWH Regional 
Hb < 80g/l 
(fit patient)  
Hb 80-100g/l 
(if symptoms 
of anaemia) 
24 
Wang 2016 77 
TXA 10mg/kg just 
before the operation  
Placebo (Saline) 
Uncemented 
LMWH + 
mechanical 
General 
Hb < 70g/l 
(fit patient)  
Hb 70-100g/l 
(if symptoms 
of anaemia) 
24 
Wang 2016 80 
TXA 15mg/kg just 
before the operation  
Placebo (Saline) 
Uncemented 
LMWH + 
mechanical 
General 
Hb < 70g/l 
(fit patient)  
Hb 70-100g/l 
(if symptoms 
of anaemia) 
24 
Yamasaki 
2004 
40 
TXA 1 gram just before 
operation 
Control: None 
Uncemented None Regional None 24 
 
The majority were small studies with participant numbers ranging from 36 to 124. However, 
they were relatively well designed and QAS was high in most of the studies with a mode of 
24 (Garneti and Field, 2004, Niskanen and Korkala, 2005, Benoni et al., 2000, Benoni et al., 
2001, Husted et al., 2003, Johansson et al., 2005, Yamasaki et al., 2004, Oremus et al., 2014, 
Wang et al., 2016, Barrachina et al., 2016, Hsu et al., 2015) (the highest possible score) and a 
range of 14-24. Only one study had a score of less than 20 (Ido et al., 2000). (Table 3.2) 
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Trials performed were all primary for THA with osteoarthritis as the commonest diagnosis. A 
placebo (normal saline) was given in 17 studies with only four studies using controls who did 
not receive any treatment (Yamasaki et al., 2004, Ido et al., 2000, Imai et al., 2012, Jaszczyk 
et al., 2015). Different doses and modes of TXA delivery were used. The doses ranged from 
10-30 mg/kg. The regimen of a single IV bolus given before the operation was used in 10 
studies (Claeys et al., 2007, Garneti and Field, 2004, Johansson et al., 2005, Yamasaki et al., 
2004, Benoni et al., 2001, Jaszczyk et al., 2015, Kazemi et al., 2010, Malhotra et al., 2010, 
McConnell et al., 2011, Wang et al., 2016). Six studies used repeated boluses (Ido et al., 
2000, Niskanen and Korkala, 2005, Benoni et al., 2000, Barrachina et al., 2016, Hsu et al., 
2015, Oremus et al., 2014) and three used a prolonged infusion (Husted et al., 2003, Lemay et 
al., 2004, Lee et al., 2013). Ekback (Ekback et al., 2000) used a regime of repeated boluses as 
well as a prolonged infusion and Imai (Imai et al., 2012) trialled different regimes including 
single and repeated boluses against a saline placebo. All studies except Ido, Yamasaki, 
Garneti and McConnell (Ido et al., 2000, Garneti and Field, 2004, Yamasaki et al., 2004, 
McConnell et al., 2011) used LMWH with or without mechanical prophylaxis for DVTs. The 
former two did not use any chemical prophylaxis, Garneti (Garneti and Field, 2004) used 
mechanical prophylaxis only and McConnell (McConnell et al., 2011) used a combination of 
aspirin and mechanical prophylaxis. Eleven studies stated a transfusion trigger which was 
related to a drop in either haemoglobin or haematocrit levels (Claeys et al., 2007, Niskanen 
and Korkala, 2005, Ekback et al., 2000, Husted et al., 2003, Lemay et al., 2004, Johansson et 
al., 2005, Barrachina et al., 2016, Hsu et al., 2015, Lee et al., 2013, Oremus et al., 2014, 
Wang et al., 2016). There were 12 trials which used solely regional anaesthesia (Claeys et al., 
2007, Garneti and Field, 2004, Ekback et al., 2000, Husted et al., 2003, Johansson et al., 
2005, Yamasaki et al., 2004, Lemay et al., 2004, Barrachina et al., 2016, Jaszczyk et al., 
2015, Kazemi et al., 2010, Malhotra et al., 2010, Oremus et al., 2014), one trial did not 
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mention the type of anaesthetic used (Ido et al., 2000) and the rest used a combination of 
general and regional anaesthesia (Niskanen and Korkala, 2005, Benoni et al., 2001, Benoni et 
al., 2000, Imai et al., 2012, Lee et al., 2013, McConnell et al., 2011). Cemented prostheses 
were used in 7 trials (Ido et al., 2000, Garneti and Field, 2004, Niskanen and Korkala, 2005, 
Benoni et al., 2001, Benoni et al., 2000, Johansson et al., 2005, Ekback et al., 2000), 
uncemented in 11 trials (Yamasaki et al., 2004, Barrachina et al., 2016, Hsu et al., 2015, Imai 
et al., 2012, Jaszczyk et al., 2015, Kazemi et al., 2010, Lee et al., 2013, McConnell et al., 
2011, Oremus et al., 2014, Wang et al., 2016, Malhotra et al., 2010), hybrid in one study 
(Claeys et al., 2007) and the rest used a combination of cemented, uncemented or hybrid 
prostheses (Husted et al., 2003, Lemay et al., 2004). The amount of blood units transfused per 
patient, functional hip and general quality of life outcome measures were not analysed as 
there was insufficient data to support detailed analysis. No studies reported on mortality in 
their series of patients. Cost comparison between TXA and blood products was analysed in 
four studies (Benoni et al., 2001, Niskanen and Korkala, 2005, Johansson et al., 2005, Husted 
et al., 2003) and favoured the use of TXA. 
3.3.2 Effects of Interventions  
3.3.2.1 Wound Complications including Infections 
All studies reported on wound complications and infections which included 679 patients in 
the TXA group and 573 patients in the control group. There were three infections in the 
control group and two in the TXA group. Johansson (Johansson et al., 2005) reported two 
superficial wound infections and Wang (Wang et al., 2016) one in the control group which 
were treated with antibiotics and no further complications occurred. In the TXA group, one 
patient developed a superficial infection (Niskanen and Korkala, 2005) and the other a deep 
infection which was re-operated on after 5 months of the primary procedure (Benoni et al., 
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2001). Additionally, 38 wound complications including wound discharge, erythema and 
haematomas occurred in the control group and 25 in the TXA group (Wang et al., 2016, 
Benoni et al., 2001, Benoni et al., 2000, Niskanen and Korkala, 2005). Overall, TXA led to a 
3% reduction in the risk of developing wound complications including infections compared 
to the control group with no significant statistical heterogeneity among the study groups 
(Risk difference -0.03, 95%, confidence interval CI -0.05 to -0.01, P-value 0.01, 
Heterogeneity I
2
 =4%). (Figure 3.2) 
Figure 3.2 Wound complications including infections forest plot analysis. The black 
diamond signifies that the mean difference is in favour of TXA. The size of each square 
depends on the weight of each study as detailed in the forest plot. A green coloured square is 
given to continuous outcomes and a blue square to dichotomous outcomes. 
 
3.3.2.2 Blood Loss: 
3.3.2.2.1 Intraoperative Blood Loss 
Eleven studies (Ekback et al., 2000, Claeys et al., 2007, Lemay et al., 2004, Johansson 
et al., 2005, Yamasaki et al., 2004, Barrachina et al., 2016, Hsu et al., 2015, Kazemi et 
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al., 2010, Lee et al., 2013, Malhotra et al., 2010, Oremus et al., 2014) with a total of 
688 patients were eligible for this outcome. Using TXA significantly reduced 
intraoperative blood loss as measured by weighing sponges and suction drainage by 
an average of 132.58 ml (95%CI -154.59 to -110.56, P <0.01). However, there was 
significant heterogeneity among the studies included (I
2
 =83%). (Figure 3.3) 
Figure 3.3 Intraoperative Blood Loss Forest Plot Analysis 
 
3.3.2.2.2 Postoperative Blood Loss  
Thirteen studies (Yamasaki et al., 2004, Ekback et al., 2000, Ido et al., 2000, 
Johansson et al., 2005, Claeys et al., 2007, Lemay et al., 2004, Garneti and Field, 
2004, Barrachina et al., 2016, Hsu et al., 2015, Lee et al., 2013, Malhotra et al., 2010, 
Oremus et al., 2014, Wang et al., 2016) including 872 patients were eligible for this 
outcome. Using TXA significantly reduced postoperative blood loss as measured by 
drain volume by an average of 235.56 ml (95%CI -252.53 to -281.60, P-value <0.01). 
However, there was significant heterogeneity among the studies included (I
2
 =91%). 
(Figure 3.4) 
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Figure 3.4 Postoperative Blood Loss Forest Plot Analysis 
 
3.3.2.2.3 Total Blood Loss 
TXA had a similar effect on total blood loss as it significantly reduced it by an 
average of 351.68 ml (95%CI -394.25 to -309.11, P< 0.01). However, again there was 
significant heterogeneity (I
2
 =80%) among the studies included (Garneti and Field, 
2004, Ekback et al., 2000, Johansson et al., 2005, Yamasaki et al., 2004, Claeys et al., 
2007, Lemay et al., 2004, Barrachina et al., 2016, Hsu et al., 2015, Lee et al., 2013, 
McConnell et al., 2011, Oremus et al., 2014, Wang et al., 2016). (Figure 3.5) 
Figure 3.5 Total Blood Loss Forest Plot Analysis 
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3.3.2.3 Blood transfusion 
Fifteen studies (Benoni et al., 2001, Benoni et al., 2000, Johansson et al., 2005, Claeys et al., 
2007, Husted et al., 2003, Niskanen and Korkala, 2005, Garneti and Field, 2004, Barrachina 
et al., 2016, Imai et al., 2012, Jaszczyk et al., 2015, Kazemi et al., 2010, Lee et al., 2013, 
Malhotra et al., 2010, Oremus et al., 2014, Wang et al., 2016) with a total of 1164 patients. 
TXA led to an 18% reduction in blood transfusion requirements (RD -0.18, 95%CI -0.23 to -
0.14, P-value <0.01, I
2
 =81%). (Figure 3.6)  
Figure 3.6 Blood Transfusion Forest Plot Analysis 
 
3.3.2.4 Complications: 
3.3.2.4.1 Deep Vein Thrombosis 
Sixteen trials (Garneti and Field, 2004, Johansson et al., 2005, Husted et al., 2003, 
Benoni et al., 2000, Benoni et al., 2001, Ekback et al., 2000, Lemay et al., 2004, 
Niskanen and Korkala, 2005, Yamasaki et al., 2004, Claeys et al., 2007, Barrachina et 
al., 2016, Hsu et al., 2015, Imai et al., 2012, Jaszczyk et al., 2015, Kazemi et al., 2010, 
Lee et al., 2013, Wang et al., 2016) reported on DVT with a total number of 1265 
patients of whom 633 received TXA. There was no significant difference among the 
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study groups in relation to a higher risk of developing DVTs (P-value 0.82). (Figure 
3.7) 
Figure 3.7 DVT Forest Plot Analysis  
           
3.3.2.4.2 Pulmonary Embolism 
There were four reported events of PE in the 21 trials we studied (Benoni et al., 2001, 
Garneti and Field, 2004, Imai et al., 2012); three in the TXA group and one in the 
control group. However, there was no statistical significance in the risk of developing 
among the groups (P-value 0.60). (Figure 3.8) 
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Figure 3.8 PEs Forest Plot Analysis  
          
3.3.2.4.3 Other Complications 
In this section, we compared all other reported adverse events among the groups. 
Systematic complications reported included one case of a brief respiratory arrest 
related to delay in volume replacement from early postoperative blood losses treated 
with no complications (Lemay et al., 2004), a case of delirium in the postoperative 
period from unrecognised alcohol withdrawal necessitating re-intubation in the post 
anesthesia care unit (Lemay et al., 2004), a patient who went into urinary retention and 
was treated with a suprapubic catheter (Niskanen and Korkala, 2005), a patient who 
had transient chest discomfort and fever 4 weeks after the operation which settled 
spontaneously (Benoni et al., 2000), a patient who had nausea on administration of the 
drug (Benoni et al., 2001) and a case of lower limb oedema and a viral infection in the 
control group (Barrachina et al., 2016). In the TXA group, a patient developed 
transient dyspnoea on the third postoperative day (Niskanen and Korkala, 2005), a 
patient had pyelonephritis one month after the operation (Niskanen and Korkala, 
2005), a patient developed pulmonary oedema and another gastroenteritis (Barrachina 
et al., 2016) and one patient developed slight hemiparesis 58 days postoperatively but 
a CT scan of her brain was normal. A CT scan performed 3 months later, after another 
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episode, showed signs of older infarctions in the right hemisphere (Benoni et al., 
2001). Overall, the results showed that using TXA was associated with fewer such 
complications. However, this did not reach a statistically significant level (P=0.17). 
(Figure 3.9) 
Figure 3.9 Other Complications Forest Plot Analysis 
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3.4 Discussion 
There are several issues related to quality control in conducting a meta-analysis; particularly 
study selection and homogeneity of these studies. A systematic review and meta-analysis 
with homogeneity is regarded as level Ia evidence. Hence, this study focused on the use of 
intravenous TXA in THA as a single group to reduce heterogeneity related to other routes of 
tranexamic application, other antifibrinolytic agents and other types of surgeries.  
The most significant result of this meta-analysis is the consistency of TXA in reducing 
wound complications after primary THAs with no heterogeneity in the studies included. The 
effect of TXA on wound healing has never been analysed in meta-analyses of RCTs 
previously which could be an important addition to the advantages of using TXA in hip 
replacement surgery. Similarly, TXA reduced blood loss and allogeneic blood transfusion 
requirements. However, there has been significant heterogeneity among the studies 
evaluating these outcomes. Despite our best efforts to produce comparable outcomes, 
variations which may have accounted for such heterogeneity include the following: 
1. The difference in sample sizes 
2. The variation of patients’ demographics such as age and severity of the underlying 
illness 
3. Inclusion and exclusion criteria for each study 
4. The differences in management protocols and logistics between treating centres 
including surgical technique and procedure, type of anaesthesia, TXA doses, the time 
and mode of administration, blood transfusion trigger and DVT prophylaxis 
5. Different strategies for measuring the outcomes. For example, postoperative blood 
loss was measured at 12, 24, 36 and 48 hours postoperatively according to the study 
performed. 
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Two studies included in the meta-analysis did not support the routine use of TXA in THA in 
relation to blood loss and transfusion requirements. Benoni 2000 (Benoni et al., 2000) 
performed a randomised double-blinded RCT on 39 THAs where TXA was given at the end 
of the operation and 3 hours later in 20 patients and an equivalent protocol of normal saline 
was given to 19 patients. Results showed that TXA did not significantly reduce intra or 
postoperative blood loss (550ml vs. 500ml and 440ml vs. 450ml respectively). However, both 
the authors of the study and results of our meta-analysis relate these findings to the fact that 
TXA was given too late to show a significant effect as most of the other studies delivered 
TXA preoperatively with overall good results. Additionally, this study reported higher wound 
complications (9 vs. 16) as well as overall complications (11 vs. 15) in the control group. 
Garneti et al (Garneti and Field, 2004), on the other hand, randomised 50 patients to receive 
either a single dose of TXA or a similar volume of saline as a preoperative bolus. Results 
were in favour of the placebo group with a mean postoperative blood loss of 353ml (+/-311) 
vs. 411ml (+/-220) for the TXA group and 1340ml (+/-665) vs. 1443ml (+/-809) total blood 
loss for each group respectively. Reasons for these discrepancies from other study results are 
unclear. Patient numbers, surgical time, dose, duration, time of administration of the drug in 
relation to the surgery, and number of times the drug was administered were proposed as 
possible contributing factors by the authors. Additionally, a greater number of patients in the 
TXA group required transfusion than in the placebo group; 64% (16 of 25) of patients in the 
TXA group required transfusion compared with 56% (14 of 25) in the placebo group. 
However, this was attributed to the different transfusion strategies of the anaesthetists, one of 
whom transfused most patients unless they were young and healthy and the fact that there 
was no defined transfusion protocol which could have been a source of bias. 
There are other meta-analyses which studied the relationship between TXA and blood loss 
and/or transfusion after THA but none evaluated wound complications as the primary 
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outcome of interest. Zufferey (Zufferey et al., 2006) analysed the effect of intravenous 
antifibrinolytics including TXA, aprotinin and EACA on blood transfusion in surgeries 
including primary hip and knee arthroplasties, major orthopaedic procedures including 
revision or bilateral arthroplasty, spinal fusion or posterior spinal fixation, musculoskeletal 
sepsis and tumours. Only studies with a transfusion protocol were analysed which resulted in 
5 studies of TXA being included for the blood transfusion outcome. Results on blood 
transfusion were similar to our study with an overall favourable outcome using TXA 
especially when considering a multiple doses regimen. However, TXA effect on blood loss 
was briefly discussed as part of ‘other efficacy endpoints’ and was evaluated as a single 
group under ‘perioperative blood loss’ with no clear definition of the blood loss. 
Kagoma (Kagoma et al., 2009), (Gill and Rosenstein, 2006) (Huang et al., 2015) also 
reviewed the evidence of using TXA, EACA and aprotinin on total blood loss and transfusion 
rates in total knee and hip arthroplasties. Despite similar trends in blood conservation, all 
three antifibrinolytics were either analysed as a single group or the effects of each of them 
evaluated for both hip and knee arthroplasties. 
Ho and Ismail (Ho and Ismail, 2003) studied the effect of TXA in reducing blood transfusion 
after total hip and knee arthroplasties. However, most of the studies were on knee 
arthroplasties with only 4 studies relating to THA and 3 suitable for measuring blood 
transfusion rates. Blood loss was again collectively defined as ‘perioperative blood loss’ 
despite including results of total blood loss as well as postoperative blood loss under this 
definition when studies were analysed. There was no significant increase in risk of 
thromboembolic events associated with TXA in either study which agrees with our 
conclusions. Similar findings were reported by Wei (Wei and Liu, 2015), Khan (Khan et al., 
2015) and Gandhi (Gandhi et al., 2013) but again the authors collectively analysed patients 
 106 
 
who underwent THA and TKA and Wei (Wei and Liu, 2015) and Khan (Khan et al., 2015) 
also included all routes (oral, IV and topical) of TXA application in their analysis. Pinzon-
Florez (Pinzon-Florez et al., 2015) in a recent meta-analysis reported on TXA effect in 
reducing blood loss and transfusion rates after THA surgery. Whilst reduction in blood loss 
outcome showed significant results, the trends in lowering transfusion rates did not. Zhou 
(Zhou et al., 2013) also analysed the effect of IV TXA in reducing blood loss and transfusion 
rates in THA. Despite an overall reduction of blood loss and transfusion rates, they included 
studies which are not RCTs (Rajesparan et al., 2009, Singh et al., 2010, Clave et al., 2012) 
which was also noted in a number of the above meta-analyses as well. 
There are several strengths of this meta-analysis. First, we conducted a thorough literature 
search of RCTs, including publications in any language as well as unpublished abstracts. 
Second, the QAS was high for most of the studies included which contributes to the strength 
of point estimates and conclusions drawn from the meta-analysis. Third, the meta-analysis 
showed favourable outcomes when using TXA in reducing wound complication rates with no 
significant heterogeneity among the studies or an increased risk of thromboembolic events. 
Fourth, cost-effectiveness analyses in four studies were all in favour of using TXA over 
blood transfusion products. 
Limitations of this meta-analysis included the lack of comparison between TXA and other 
blood conservation methods such as using erythropoietin and preoperative autologous blood 
donation and postoperative autotransfusion. Additionally, trials included in our study were 
designed to assess the efficacy and safety of TXA in primary THA where an exclusion of 
high risk patients with history of cardiovascular disease and previous thromboembolic events 
was the case in most of the studies included. Therefore, no definite conclusions regarding 
TXA safety can be derived from our meta-analysis in relation to revision hip arthroplasty or 
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in high risk patients. There has not been enough data also to support the analysis of functional 
outcome scores or quality of life outcome measures as planned originally for our secondary 
outcomes. 
3.5 Conclusion 
In summary, we conclude that TXA significantly reduced wound complication rates after 
primary THA with no significant increase in complication rates. Favourable results have also 
been suggested for the blood loss and transfusion rate outcomes but with significant 
heterogeneity which necessitates careful interpretation of TXA effect in this context. 
Additionally, future randomised trials of sufficient power should be designed to examine the 
efficacy and safety of TXA in revision hip surgery and its efficacy in comparison to other 
blood conservation methods. 
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Chapter 4 
 
Is Single-stage Revision According to a 
Strict Protocol Effective in Treatment 
of Chronic Knee Arthroplasty 
Infections? 
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4.1 Introduction 
Most TKA studies today report infection in fewer than 2% of primary and 5% of revision 
procedures (Moran et al., 2007, Laffer et al., 2006, Tintle et al., 2009, Vanhegan et al., 
2012b). Nevertheless, both diagnosis and management of periprosthetic TKA infections 
remain challenging because the ability to detect and eradicate pathogens in periarticular 
structures and the magnitude of the host response to infection vary with the virulence of the 
infecting organism and the immunocompetence of the host (Haddad et al., 2000a). 
Management depends on a number of factors including the acuteness or chronicity of the 
infection, the infecting organism and its sensitivity profile to antibiotics, the health of the 
patient, the fixation of the prosthesis, available bone stock, and the particular philosophy and 
training of the surgeon (Haddad et al., 2000a, Zimmerli and Ochsner, 2003, Oussedik et al., 
2012). 
Two-stage revision remains the standard for treatment of chronic TKA infections because 
many series report the successful eradication of a PJI in more than 90% of patients using this 
approach (Zimmerli et al., 2004, Haddad et al., 2000a, Laffer et al., 2006). Furthermore, it 
permits the use of allografts, which is particularly important given the frequency of femoral 
and tibial defects associated with TKA infections (Haddad et al., 2000b, Lai et al., 1996). 
Nevertheless, this procedure is costly, time-consuming, and may result in increased damage 
to bone and surrounding soft tissues (Vanhegan et al., 2012b).  
Single-stage revision in selected cases has become an appealing alternative because it 
involves only one surgical procedure and, if comparably effective, will be associated with 
less patient morbidity and potentially improved functional outcomes and less expense 
(Oussedik et al., 2010, Gulhane et al., 2012, Vanhegan et al., 2012b). Eradication of infection 
using a single-stage strategy in selected patients is achieved in 67% to 95% of patients 
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(Buechel et al., 2004, Goksan and Freeman, 1992, Silva et al., 2002, Singer et al., 2012, Lu et 
al., 1997, Sofer et al., 2005, von Foerster et al., 1991).  
 
At our institution, we carry out single-stage TKA revisions for chronic infections in very 
selected circumstances and, therefore, we determined in this study (1) the degree to which our 
protocol of a highly selective single-stage revision approach achieved infection-free survival 
compared with a two-stage revision approach to TKA infections; and (2) Knee Society scores 
and radiographic evidence of implant fixation between the single-stage and two-stage patients 
who were treated for more complicated infections. 
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4.2 Patients and Methods 
We performed a retrospective cohort analysis of a prospectively compiled register of all 102 
patients diagnosed with chronic infected TKAs of whom 28 (27%) were treated using a 
single-stage approach and 74 (73%) were treated using a two-stage approach between 2004 
and 2009. All patients were available for follow-up at a minimum of 3 years (mean, 6.5 
years; range, 3-9 years). 
In the two-stage revision group, 12 patients had undergone two and 24 undergone one 
previous aseptic revision. There were no prior revision procedures in the remaining 38 
patients. In the single-stage group, eight patients had undergone aseptic revisions and the rest 
were primaries. 
At our institution, a patient  with suspected TKA infection is promptly referred to the knee 
surgeons who deal with PJIs regularly because this is a specialised procedure and there is no 
role for simple incision and drainage or repetitive washouts, which result in emergence of 
resistant microorganisms (Vanhegan et al., 2012b). Clinical presentation (pain, fever, 
swelling, skin redness, discharging sinus), serologic testing (erythrocyte sedimentation rate 
[ESR] > 30 mm/hour; C-reactive protein [CRP] > 10 mg/L), knee aspiration, and biopsy 
samples help us diagnose PJI (Sukeik and Haddad, 2009c, Vanhegan et al., 2012b). 
Definitive diagnosis, however, is established when three to six specimens are sampled from 
different sites at the time of surgery (e.g., capsule, femur and tibia) and the same 
microorganism is cultured from at least three specimens (Zimmerli and Ochsner, 2003, 
Atkins et al., 1998, Vanhegan et al., 2012b).  
A decision to perform surgery was based on either growing a microorganism from the tissue 
aspiration/biopsies or presence of a sinus tract communicating with the prosthesis. A 
microorganism was identified preoperatively in all single-stage patients and in 65 of the two-
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stage patients, whereas the remaining nine patients were identified postoperatively only 
despite the presence of a discharging sinus in five patients. The remaining four patients had 
compelling evidence of PJI with elevated inflammatory markers, loose prostheses, and 
purulence on aspiration of the joints despite the absence of an isolated microorganism. 
We graded all patients according to a standardised protocol for chronic hip and knee PJIs 
based on the criteria previously set out by Haddad (Haddad et al., 1999) and considered them 
for either a single- or two-stage revision procedure accordingly. The indications for using a 
single-stage approach during the period in question included (1) insignificant bone loss (e.g. 
Anderson Type III defects (Engh and Ammeen, 1999, Engh and Parks, 1997)] or a soft tissue 
defect that could be closed primarily; (2) non-immunosuppressed hosts: patients who are not 
rheumatoid or diabetic or on immunosuppressant medication and did not have ongoing sepsis 
elsewhere or chronic disease such as anaemia or cancer; and (3) isolation of a single low 
virulent organism preoperatively, which is sensitive to bactericidal antibiotic treatment. 
Hence, we excluded polymicrobial infections and multi-resistant organisms such as MRSA 
and MRSE and included appropriate patients only after discussion with our microbiologist 
colleagues. If patients had any of the contraindications, they underwent a two-stage revision 
instead. 
There were 28 patients in the single-stage group with a mean age of 63 years (range, 48-87 
years) and equal distribution of 14 women and men. On the other hand, the two-stage group 
included 74 patients with a mean age of 68 years (range, 45-85 years) 41 of them were 
women and 33 were men. Overall there were 12 patients with sinus tracts communicating 
with the prosthesis all in the two-stage group. No bilateral infections were included in our 
study. No patient had a history of infection of the affected knee. The majority of patients had 
osteoarthritis as the underlying pathology for their primary TKA (74 patients) followed by 
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inflammatory arthropathy (20 patients) and posttraumatic/acute vascular necrosis resulting in 
secondary osteoarthritis in eight patients. In patients who had undergone revision TKA, the 
original indications for reoperation after their primary procedures were aseptic loosening and 
wear. Comorbidities were assessed according to the American Society of Anaesthesiologists 
(ASA) grading system (Little, 1995); nine patients were Grade I, 56 Grade II, and 37 Grade 
III. Three patients died during the follow-up period but had a minimum of 2 years’ data 
available for analysis. No patients were recalled specifically for this study; all data were 
obtained from medical records and radiographs. 
 
4.3 Surgical Technique: Single-stage Revision 
The operation consists of open aggressive débridement with removal of all components and 
cement, during which multiple samples are sent to microbiology before administration of 
antibiotics and the knee is irrigated with hydrogen peroxide and Betadine
®
 solutions (Videne, 
Ecolab Ltd, Swindon, UK) and pulsatile lavage. The wound is then soaked in aqueous 
Betadine
®
 and the wound edges are approximated. The patient is then re-draped, the surgical 
team rescrubs, and new instruments are used. After a further lavage, implantation of a new 
prosthesis is performed using ALC according to known sensitivities at a volume of < 5% of 
the total weight of cement powder.  For example, we commonly used 1 g vancomycin and 1 g 
gentamicin per 40-g bag of Palacos
®
R (Heraeus Medical, Wehrheim, Germany) for our 
single-stage revisions. Postoperatively, patients continue antibiotic therapy tailored to the 
sensitivities of intraoperative cultures for at least 6 weeks until inflammatory markers (CRP, 
ESR) and nutritional markers such as plasma albumin concentration return to stable limits 
(levels normalised in 90% of cases). Normal levels were defined as an ESR < 30 mm/hour, 
CRP < 10 mg/L, and albumin 35 to 50 g/L. The change from intravenous to oral therapy is 
effected as soon as we have a full organism sensitivity profile and after consultation with our 
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infectious diseases team with whom we have a fortnightly multidisciplinary meeting (IV 
antibiotics for 1 week: four patients, 2 weeks: seven patients, 6 weeks: 17 patients). Long-
term oral suppressive antibiotic therapy was not used in any patients after IV treatment had 
concluded.   
4.4 Surgical Technique: Two-stage Revision 
Intraoperatively, the first part of the operation is similar to a single-stage revision. However, 
after rescrubbing and re-draping, a temporary articulating ALC spacer is implanted instead. 
This spacer normally contains 3 g vancomycin and 2 g gentamicin per sachet of Palacos
®
R 
(Heraeus Medical), which provides a broad spectrum of coverage for organisms commonly 
encountered with deep periprosthetic infections while reducing the development of resistant 
strains (Anagnostakos et al., 2006). Postoperatively, the patient is allowed to mobilise partial 
weightbearing with crutches and is discharged home when deemed safe. All patients had IV 
antibiotics for the first 5 days and then either IV or oral antibiotic therapy was continued and 
tailored to the sensitivities of intraoperative cultures and continued for 6 weeks (seven 
patients had 2 weeks of IV and then oral antibiotics, five had 6 weeks of IV antibiotics). The 
decision to proceed with insertion of a new prosthesis is determined by the clinical response 
of the patient including wound healing and inflammatory and nutritional markers indicating 
resolution of infection, which is confirmed after 2 weeks of discontinuing any antibiotics the 
patient was taking and performing a further aspiration which came back as negative for 
infection. At the second stage, the spacer is removed and the underlying cement mantle is 
fragmented and removed piecemeal without sacrificing bone stock. An appropriate prosthesis 
is then reimplanted with cemented components, and allografts may be used in cases of severe 
bone loss. Types of implants and augments used are listed (Table 4.1). 
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Table 4.1 Types of implants/reconstructions used for the single and two-stage revisions of 
infected TKAs 
 Single-
stage 
Two-stage 
Augments 4 9 
Cones 2 5 
Stems on one side or both 28 74 
Semi-Constrained Implants 18 50 
Hinges 7 19 
Bone Graft 0 6 
 
Regardless of the treatment strategy followed, we review all our patients postoperatively at 6 
weeks, 6 months, 1 year, and then on a yearly basis looking for clinical symptoms and signs 
of infection as well as CRP and ESR. Professor Haddad performed all the procedures. We 
obtain plain radiographs including AP, lateral, and skyline views of both knees at every 
follow-up appointment. We assess component position, radiolucencies/osteolysis, and 
loosening according to the American Knee Society recommendations (Ewald, 1989 , Sarmah 
et al., 2012). Distinguishing infective loosening from aseptic loosening radiographically can 
be difficult; however, signs of an infected knee arthroplasty include progressively enlarging 
lucencies, endosteal scalloping, periostitis, and focal lysis (Sarmah et al., 2012)]  
Eradication of infection is defined as absence of clinical, serologic, and radiographic signs of 
infection and absence of death secondary to infection or treatment during the follow-up 
period. We used the MSIS criteria in our last outpatient review to assess and confirm 
eradication of infection (Parvizi et al., 2011b). We define failure as any major operation 
performed in any subgroup of patients for eradication of infection, including a two-stage 
revision, excision arthroplasty, arthrodesis, and amputation, or the need for long-term 
antibiotic suppression. We consider reinfection to be an infection with the same or another 
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organism. The mean interval time between each stage was 62 days (range, 42-119 days). 
Duration of antibiotic treatment was 63 days (range, 42-85 days) for the single-stage group 
and 12 days (range, 5-42 days) for the two-stage group.  
The causative microorganism was identified preoperatively in all single-stage patients and in 
65 of the two-stage patients, whereas the remaining nine patients were identified 
postoperatively. Microbiology from intraoperative tissue sampling confirmed bacterial 
infection in all patients with the most commonly isolated organism being coagulase negative 
Staphylococcus (34 patients [33%]) of which nine were methicillin-resistant followed by S 
aureus (33 patients [32%]), of which 11 were methicillin-resistant (Table 4.2). 
Table 4.2 Microorganisms grown from intraoperative tissue biopsies 
Microorganism Single- stage Two-stage 
Staphylococcus aureus  
(methicillin-resistant S aureus) 
8  
(0) 
25  
(11)  
Coagulase-negative Staphylococcus 
(methicillin-resistant Staphylococcus 
epidermidis) 
11  
(0) 
23  
(9)  
Streptococcus 4 12 
Gram-negatives  4 13 
Anaerobes 1 7 
Candida/Mycobacterium tuberculosis 0 4  
Polymicrobial 0 10  
 
Other microorganisms isolated included Gram-negatives (17 patients), Streptococcus (16 
patients), anaerobes (eight patients), Candida (three patients) and Mycobacterium 
tuberculosis (one patient). Ten patients had polymicrobial infections. Most common 
reinfections were the result of polymicrobial infections (Fig. 4.1). 
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Figure 4.1 Micro-organisms responsible for infections and re-infections, CNS: Coagulase 
Negative Staphylococcus
 
The functional outcome for all patients was evaluated using the Knee Society scoring system, 
which was recorded preoperatively and at the 2-year follow-up. 
Statistical analysis was carried out using the two-sample t-test or Mann-Whitney U-test for 
continuous outcomes and a chi square test or Fisher’s exact test for categorical outcomes. 
4.5 Results 
None of the patients in the single-stage revision group developed recurrence of infection, and 
five patients (7%) in the two-stage revision group developed reinfection (p = 0.16).  Those 
patients, however, underwent a further two-stage revision procedure and had their infections 
eradicated at last follow-up.  
The Knee Society score was higher in the single-stage group at 2 years than in the two-stage 
group (mean 88 (range 38-97) versus 76 (range 29-93, p < 0.001). Both groups improved in 
this score after successful reconstruction from a mean of 32 (range 18-65) to a mean of 88 
(range 38-97) in the single-stage group and 31 (range 17-70) to 76 (range 29-93) in the two-
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stage group (Table 4.3). Radiographic findings showed a well-fixed prosthesis in all patients 
of both groups with no evidence of loosening at the most recent follow-up. 
 
Table 4.3 Knee Society scores and visual analogue scale satisfaction scores 
Outcomes  Single-
stage 
Two-stage p value 
Number of patients 28 74 N/A 
Recurrent infection 0 5 < 0.01 
KSS preoperatively 32 (18-65) 31 (17-70) NS 
KSS at 2 years 88 (38-97) 76 (29-93) < 0.02 
Difference in KSS 56 45 < 0.02 
Visual analogue scale 
at 2 years 
7.82 6.18 < 0.01 
Ranges in parentheses; KSS = Knee Society score; N/A = not applicable; NS = not 
significant. 
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4.6 Discussion 
Despite the relatively low rates of PJIs after TKAs, they remain a leading cause of revision 
surgery as a result of an ever increasing number of knee arthroplasties performed yearly for 
an aging population (Vanhegan et al., 2012b, Haddad et al., 2000a). In contrast to two-stage 
revisions, single-stage surgery may offer a shorter hospital stay, the avoidance of 
complications associated with a second operation, improved postoperative function and pain, 
and lower cost; however, whether eradication of infection is sacrificed for these endpoints 
remains controversial, and if it is, a single-stage approach would likely not be justified. In this 
study, we therefore determined (1) the degree to which our protocol of a highly selective 
single-stage revision approach achieved eradication of infection compared with a two-stage 
revision approach to TKA infections; and (2) Knee Society scores and radiographic evidence 
of implant fixation between the single-stage and two-stage patients who were treated for 
more complicated infections. 
Our study is associated with some limitations. First, a single-stage revision procedure was 
applied in a highly selected patient population using the indications we have defined (Table 
4.1) and is not suitable for all chronic infections. Second, patients undergoing two-stage 
procedures tend to have been more complicated taking into consideration that they had 
undergone multiple revision procedures, and had less bone stock to start off with, which may 
account for the more complex reconstructions and the higher observed Knee Society scores in 
the single-stage patients. Third, eradication of infection after knee arthroplasties can be 
affected by a number of risk factors, including age, sex, time from operation, duration of 
symptoms, patient comorbidities, and the pathogen causing the infection (Della Valle et al., 
2004, Haddad et al., 2000a, Vanhegan et al., 2012b). Because of the small number of patients 
within each subgroup, the heterogeneity of the study population and the retrospective nature 
of this study with some data occasionally missing such as the type of implants used in the 
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primary operations, number of previous revisions, comorbidities and risk factors for 
infection, we were unable to perform a multivariate analysis to further investigate the effect 
of those risk factors on eradication of infection. Fifth, despite no recurrence of infection in 
the single-stage group of patients, the numbers included in this study remain small. This, 
however, reflects the difficulty of finding large numbers suitable for a single-stage revision 
even at a tertiary center dealing with significant numbers of periprosthetic infections. 
Our results for eradicating infection using two-stage revision for chronic infections are 
consistent with those previously reported in the literature, especially where a clear protocol 
has been followed (Laffer et al., 2006, Meek et al., 2003, Haddad et al., 2000a, Zimmerli et 
al., 2004, Leone and Hanssen, 2005, Pitto et al., 2005, Barrack et al., 2000, Freeman et al., 
2007, Haleem et al., 2004). It is of note, however, that the inclusion and exclusion criteria as 
well as management protocols and definition of infection varied among those studies, 
occasionally including all four types of periprosthetic infections rather than chronic infections 
only. Additionally, some of the studies did not differentiate between knees and hips when 
reporting their results, which resulted in a wide range of infection-free survival. On the other 
hand, single-stage revisions for chronic infections are regaining momentum and our results 
certainly reflect a strict protocol, which has led to infection-free survival in all cases selected 
for single-stage revision (Buechel et al., 2004, Goksan and Freeman, 1992, Lu et al., 1997, 
Silva et al., 2002, Singer et al., 2012, Sofer et al., 2005, von Foerster et al., 1991). (Table 4.4)  
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Table 4.4 Previous studies reporting infection eradication after single-stage revision for 
infected TKAs  
Study Number 
of cases 
Infection       
eradication % 
Follow-up 
(years) 
Buechel et al, 2004 [4] 22 90.9 10.2 
Goksan and Freeman, 
1992 [10] 
18 88.8 5 
Lu et al, 1997 [20] 8 87.5 1.7 
Silva et al, 2002 [30] 37 89.2 4 
Singer et al, 2012 [31] 63 95 3 
Sofer et al, 2005 [32] 15 93 1.5 
von Foerster et al, 1991 
[36] 
104 73.1 6.3 
 
The only study with equivalent results to our study reporting 100% infection-free survival 
with a single-stage strategy was recently published by Parkinson (Parkinson et al., 2011). 
However, in their 12-patient series, they did not mention details about the inclusion criteria 
for their protocol apart from growing a microorganism from the arthroscopy performed 
preoperatively for a diagnosis of infection. Additionally, there are no details regarding the 
type of infection treated (acute or chronic, postoperative or hematogenous).  
Other studies also reported improvement in Knee Society scores after a single-stage revision 
for PJI. For example, Singer (Singer et al., 2012) reported a mean Knee Society score of 72 
points after 24 months and a mean reported range of movement of 104°. Buechel (Buechel et 
al., 2004) also had a similar mean final postoperative knee score of 79.5 (range, 35–94). This 
may support an easier convalescence as a potential advantage of a single-stage procedure, 
especially with no differences found in prosthesis fixation as seen in our current study at the 
latest follow up. 
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4.7 Conclusion 
In conclusion, our data suggests that single-stage revision surgery in chronic TKA infections 
achieve a high rate of infection-free survival when patients are carefully selected. However, 
larger, multicenter, prospective trials are called for to validate our findings. 
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Chapter 5 
 
PJI after THA: The Ten Year Outcomes 
of an Algorithmic Approach 
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5.1 Introduction 
Health services are experiencing an exponential global rise in numbers of lower limb 
arthroplasty procedures performed for an ageing population. Over the last 5 years, the UK 
National Health Service witnessed a growth of hip and knee arthroplasty procedures by 
4000–5000 cases/year (NJR, 2011). Subsequently, even a minimal prosthetic joint infection 
(PJI) rate of 0.57% constitutes a major concern (Phillips et al., 2006) especially with the 
financial burden of a single revision procedure for sepsis exceeding £21,000 (Vanhegan et al., 
2012a). The picture is further complicated by the continuous metamorphosis and emergence 
of new resistant bacterial strains as well as infections with rare organisms (Chodos and 
Johnson, 2009, Eid et al., 2007). 
Challenges including diagnostic uncertainty, immunocompromised patients, recurrent 
infection, infection around a well-fixed implant and substantial bone loss require careful 
preoperative assessment and well defined treatment plans (Haddad et al., 1999). However, 
until recently there has been no consensus over a standard treatment strategy for PJIs which 
has accounted for the extensive variability in infection eradication rates in the literature 
(Kaltsas, 2004, Ahlberg et al., 1978, Antti-Poika et al., 1989, Canner et al., 1984, Crockarell 
et al., 1998, Poss et al., 1984, Tsukayama et al., 1996, Stinchfield et al., 1980, Giulieri et al., 
2004, Moyad et al., 2008). Therefore, specialist tertiary centres dealing with such infections 
on a regular basis using a multidisciplinary approach and clearly defined protocols may 
improve infection rates and contribute to standardising management of PJI after THA. 
Our protocol involves aggressive surgery removing all mobile and non ingrown parts and 
exchanging them at the same sitting for acute infection, and a selective single stage versus 
two stage strategy for established infections based on host, organism and local factors.  
 
 125 
 
 
We determined in this study (1) the rate at which our protocol eradicated THA infections, (2) 
the most common microorganisms responsible for both infections and reinfections, and (3) 
the final treatment modality resulting in infection-free survival for each patient at the last 
follow-up. 
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5.2 Protocol 
At our institution, in a case of suspected THA infection, the patient is promptly referred to the 
hip team who deal with PJIs regularly as this is a specialised procedure and there is no role 
for simple incision and drainage or repetitive washouts which result in emergence of resistant 
microorganisms (Haddad et al., 1999, Sukeik and Haddad, 2009c). Clinical presentation 
(pain, fever, swelling, skin redness, discharging sinus), serologic testing (erythrocyte 
sedimentation rate [ESR] > 30 mm/hour; C-reactive protein [CRP] > 10 mg/L), hip aspiration 
and biopsy samples help us diagnose PJI (Sukeik and Haddad, 2009c). Definitive diagnosis 
however, is established when three to six specimens are sampled from different sites at the 
time of surgery (e.g. capsule, femur and acetabulum) and the same microorganism is cultured 
from at least three specimens (Zimmerli and Ochsner, 2003, Sukeik and Haddad, 2009c, 
Atkins et al., 1998). The extent of infection and the interval for which it has been present play 
a role in the choice of treatment and the chances for successful eradication of infection as 
follows: 
5.2.1 Acute Infection 
We define it as an infection occurring within 6 weeks of the index operation (primary or 
revision) or of haematogenous spread from a confirmed source of infection elsewhere in a 
previously well functioning implant. In haematogenous infections, a full workup to establish 
the source of infection is undertaken preoperatively, including a comprehensive history of 
recent systemic infections or invasive procedures causing bacteremic seeding of the hip, and 
investigations performed include a throat swab, chest radiograph, and urine, stool, and blood 
cultures (Sukeik et al., 2012). Decision to perform surgery is based on a high index of 
suspicion from clinical presentation and serologic testing. However, we do not perform 
preoperative diagnostic aspiration and biopsies in acute infections as this not only delays 
surgical intervention but also carries variable sensitivity and specificity rates for diagnosing 
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infection (0.50–0.93 and 0.82–0.97, respectively (Spangehl et al., 1999, Kraemer et al., 1993, 
Lachiewicz et al., 1996). Treatment of acute infection is subdivided according to the type of 
prosthetic fixation of the original implant: 
5.2.1.1 Cemented Prostheses  
We perform an aggressive open débridement with exchange of mobile parts and retention of 
the implant in stable components with no evidence of immunosuppression, and overlying soft 
tissue and skin of good condition (Davis, 2005, Zimmerli et al., 2004). The aim of rapid 
intervention with thorough open débridement is to prevent the production of any biofilm by 
the infecting organism, paramount for successful treatment of infection (Moyad et al., 2008). 
Patients undergo an open complete synovectomy, multiple tissue sampling, exchange of 
femoral heads and acetabular inserts, débridement of all aspects of the joint, irrigation with 
hydrogen peroxide and Betadine
®
 solutions, and then pulsatile lavage. 
5.2.1.2 Cementless Prostheses  
For acute haematogenous infections in previously well functioning and well fixed implants, 
we follow the same protocol for cemented prostheses as detailed above. However, in acute 
postoperative infections, once the debridement is complete and samples are sent, all drapes, 
gowns, gloves and equipment are changed to create a new, sterile environment. We then 
proceed to a direct exchange single-stage cementless THA as this represents an ideal 
opportunity to remove both the implant and its biofilm prior to ingrowth (Hansen et al., 
2013). 
For both treatment modalities, patients continue antibiotic therapy tailored to the sensitivities 
of intraoperative cultures for at least 6 weeks until inflammatory markers (CRP, ESR) and the 
plasma albumin concentration return to within normal limits. Early conversion to oral 
antibiotics is dictated by sensitivities and consultation with our microbiology team with 
whom we have a fortnightly multidisciplinary meeting. 
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5.2.2 Chronic infection 
In chronic PJIs, our protocol includes careful assessment of local soft tissues, baseline CRP 
and ESR, and hip aspiration combined with tissue biopsy as this has shown improved 
sensitivity and accuracy for diagnosing infection after at least 4 weeks of discontinuing any 
antibiotic therapy (Meermans and Haddad, 2010). We also perform plain anteroposterior and 
lateral radiographs, with additional CT if deemed necessary for further acetabular assessment. 
Once diagnosis of PJI is suggested by clinical findings and investigations, all patients are 
graded by the standardised protocol based on the criteria previously set out by Haddad et al 
(Haddad et al., 1999) (Table 4.1) and accordingly are either considered for single or two-
stage revision procedure. 
5.2.2.1 Single Stage Revision  
At our institution single-stage revision is carried out under strict conditions including: 
minimal/moderate bone loss, non-immunocompromised patients, healthy soft tissues, a 
known organism with known sensitivities and when appropriate antibiotics are available. The 
operation is split into two parts; the first consists of an open aggressive debridement with 
removal of all components and cement, during which multiple samples are sent to 
microbiology and irrigation with hydrogen peroxide and Betadine
®
 solutions, and then 
pulsatile lavage is done. The area is then soaked in aqueous betadine and the wound edges 
approximated. This is considered to be the end of the first part of the operation and the patient 
is re-draped and new instruments are used. The surgical team rescrubs and put on new gowns. 
After a further lavage, implantation of a new prosthesis is performed using ALC or antibiotic 
loaded bone graft as needed. Patients continue antibiotic therapy tailored to the sensitivities 
of intraoperative cultures for at least 6 weeks until inflammatory markers (CRP, ESR) and the 
plasma albumin concentration return to within normal limits. The change from intravenous to 
oral therapy is effected as soon as we have a full organism sensitivity profile. 
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5.2.2.2 Two stage Revision  
This is the gold standard for treatment of chronically infected and complex THA infections as 
the successful eradication of a PJI is over 90% (Haddad et al., 2000b, Sukeik and Haddad, 
2009b, Bejon et al., 2010, Biring et al., 2009, Cooper and Della Valle, 2013). 
Intraoperatively, the first part of the operation is similar to a single stage revision. However, 
after rescrubbing and re-draping, a temporary articulating ALC spacer is implanted instead. 
This spacer normally contains 3 g of vancomycin and 2 g of gentamicin per sachet of Palacos 
R which provides a broad spectrum of coverage for organisms commonly encountered with 
deep periprosthetic infections whilst reducing the development of resistant strains. 
(Anagnostakos et al., 2006) Postoperatively, the patient is allowed to mobilise partial weight-
bearing with crutches and is discharged home when deemed safe. Antibiotic therapy tailored 
to the sensitivities of intraoperative cultures is continued for 4 to 6 weeks. The decision to 
proceed with insertion of a new prosthesis is determined by the clinical response of the 
patient including wound healing, inflammatory and nutritional markers indicating resolution 
of infection together with performing a further aspiration which is negative. At the second 
stage, the spacer is removed and the underlying cement mantle is fragmented and removed 
piecemeal, without sacrificing bone stock. Appropriate implants are then reimplanted with 
either cemented or cementless components, and allografts may be used in cases of severe 
bone loss. 
Regardless of the treatment strategy followed, we review all our patients postoperatively at 2 
and 6 weeks, 6 months, 1 year, and then on a yearly basis, looking for clinical symptoms and 
signs of infection, as well as CRP and ESR level testing. We obtain plain radiographs 
including an AP pelvis and lateral of both hips at every follow-up appointment. We assess 
stem position, radiolucencies and osteolysis. The stem angle is classified as neutral, varus or 
valgus. A stem angle is considered neutral if its axis is within 2 degrees of the femoral shaft 
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axis. Femoral and acetabular radiolucencies are classified according to Gruen (Gruen et al., 
1979) and DeLee and Charnley (DeLee and Charnley, 1976) zones respectively. Loosening is 
diagnosed if the radiolucent zone around one or both components is 2mm or more in width 
and a patient has symptoms on weightbearing and motion that are relieved by rest (Harkess 
and Crockarell, 2008). Osteolytic lesions are documented and classified on the basis of their 
size (linear or expansile) and their location according to previously published criteria by Zicat 
(Zicat et al., 1995). Of note though is that substantial interobserver variability can be 
expected using these systems (McCaskie et al., 1996, Kneif et al., 2005). Eradication of 
infection is defined as absence of clinical, serologic, and radiographic signs of infection and 
absence of death secondary to infection or treatment during the follow-up period. We define 
failure as any major operation performed in any subgroup of patients for eradication of 
infection, including a two-stage revision, excision arthroplasty, arthrodesis, and amputation, 
or the need for long-term antibiotic suppression. However, in acute cemented THA 
infections, we perform up to a maximum of three debridements before proceeding to any 
further surgical intervention or considering long-term antibiotic suppression, taking into 
consideration patients’ comorbidities and risks for surgery and their preference for choice of 
treatment. We consider reinfection to be an infection with the same or another organism. 
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5.3 Patients and Methods 
We performed a retrospective cohort analysis of a prospectively compiled register of all 204 
patients diagnosed with infected THAs (127 primaries, 77 revisions) and treated according to 
our protocol between 1999 and 2009. Patients included 88 men and 116 women with a mean 
age of 66.5 years (range, 39–87 years). No bilateral infections were included in our study. 
The majority of patients had osteoarthritis as the underlying pathology for their primary 
THA. (Table 5.1)  
Table 5.1 Indications for the initial total hip arthroplasty    
 
Indication Number 
OA 165 
Inflammatory arthropathy 12 
AVN 10 
DDH/SUFE/Perthes 17 
OA = osteoarthritis; AVN = avascular necrosis; DDH= developmental dysplasia of the hip; 
SUFE: slipped upper femoral epiphysis 
 
In revision THA patients, the original indications for reoperation after their primary 
procedures were aseptic loosening and wear. No patient had a previous history of infection of 
the affected hip, and none had prosthetic loosening or mal-alignment at the time of 
presentation. Comorbidities were assessed according to the ASA grading system (Little, 
1995); 32 patients were Grade 1, 90 Grade 2, 80 Grade 3 and 2 Grade 4. No patients were lost 
to follow-up.  No patients were recalled specifically for this study; all data were obtained 
from medical records and radiographs. Professor Haddad performed all the procedures. 
Minimum follow-up was 3 years (mean, 6.8 years; range, 3–12 years). 
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Patients in the acute group where a cemented THA was originally implanted (26 patients) 
underwent aggressive débridement with exchange of all mobile parts. In acutely infected 
cementless THAs (19 patients), we proceeded to a single-stage cementless revision 
arthroplasty. For both groups, the mean time between onset of hip symptoms and 
débridement/single stage revision was 19 days (range, 1-41 days). In acute hematogenous 
infections, a source of infection was identified in all patients (one upper respiratory tract 
infection, one lower respiratory tract infection, six urinary tract infections) and the bacteria 
isolated in each case was the same bacteria as cultured from the prosthetic joint. 
In chronic infections, we performed a single stage revision according to our preset criteria 
(34/159 patients) and a two-stage procedure for the rest (125 patients). In the two stage 
revision group, 21 patients had undergone 2 previous revisions, with 40 having one prior to 
2-stage intervention. There were no prior revision procedures in the remaining 64 patients. 
The causative microorganism was identified pre-operatively in 104 cases whereas the 
remaining 21 were identified post-operatively only despite the presence of a discharging 
sinus in 10 cases. The mean interval time between each stage was 9 (3-36) weeks. 
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5.4 Results 
At last follow-up, 188 of the 204 patients (92%) achieved eradication of their infections with 
no evidence of recurrence or loosening, wearing away, or malpositioning on follow-up 
radiographs. 
Microbiology confirmed bacterial infection in all patients, with the most commonly isolated 
organism being coagulase negative Staphylococcus (76 patients, 37%), followed by S aureus 
(63 patients, 31%), of which 27 were methicillin resistant (Figure 5.1). Other microorganisms 
isolated included Streptococcus 7, Enterococcus7, Corynebacterium spp 7, 
Propionibacterium spp 9, Acinetobacter 5, Pseudomonas aeruginosa 7, E coli 14, 
Bacteroides fragilis 7 and Candida spp 2.  
 
Figure 5.1 Micro-organisms grown from intraoperative tissue biopsies 
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Most common reinfections were due to coagulase-negative Staphylococcus and S aureus 
(Figure 5.2). 
 
Figure 5.2 Micro-organisms responsible for infections and re-infections 
 
In the acute cemented THAs, eight patients had repeat washouts and the infection was 
eradicated in four out of the eight cases. However, five patients eventually underwent a two-
stage revision due to reinfection and one patient was placed on long-term antibiotic 
suppression with overall 77% eradication of infection in this group of patients (we have 
recently published detailed analysis of those patients (Sukeik et al., 2012)]. In the acute 
cementless THAs, four patients underwent a two-stage revision due to reinfection with 79% 
infection-free survival. In the chronic THAs, no patient developed recurrence of infection in 
the single stage revision patients. However, six patients in the two-stage revisions developed 
reinfection with overall 95% eradication of infection. Of note is that all patients who had 
failure of their treatments underwent a further two stage revision procedure and remained 
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infection free at last follow up with the exception of the patient who went on long term 
antibiotic suppression treatment. 
During the same period of follow-up, it is worth noting that there has been another 30 
“haematomas” post THA which were washed out acutely with no microorganism grown from 
intraoperative samples and that there has been 20 “no organism” two stages that we have 
looked at separately with equivalent 95% eradication of infection. 
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5.5 Discussion 
Despite the relatively low rates of PJIs after THAs, they remain a leading cause of revision 
surgery due to an ever increasing number of hip arthroplasties performed yearly for an aging 
population. (Sukeik and Haddad, 2009c) Difficulties with reaching a consensus on what 
defines infection and which strategy best eradicates it led to extensive variability in infection 
rates in the literature. Therefore, specialist tertiary centres dealing with such infections on a 
regular basis using a multidisciplinary approach and clearly defined protocols may improve 
infection-free survival and contribute to a global approach for managing PJI. We aimed at 
determining (1) the rates at which our protocol eradicated THA infections, (2) the most 
common microorganisms responsible for both infections and reinfections, and (3) the final 
treatment modality resulting in successful treatment of infection for each patient at the last 
follow-up. 
Our study is associated with some limitations. First, eradication of infection after hip 
arthroplasties can be affected by a number of risk factors, such as age, sex, time from 
operation, duration of symptoms, patient comorbidities, and the pathogen causing the 
infection (Della Valle et al., 2004, Sukeik and Haddad, 2009c, Tsukayama et al., 1996). 
Because of the small number of patients within each subgroup and retrospective nature of this 
study, we were unable to perform a multivariate analysis to further investigate the effect of 
those risk factors on eradication of infection. Second, the study population was heterogeneous 
in relation to the type of original operation (primary versus revision), type of infection (acute 
versus chronic and postoperative versus hematogenous), type of prosthetic fixation (cemented 
versus cementless) and type of surgery performed (aggressive debridement versus single and 
two stage revisions). 
Our results for eradication of infection using aggressive early debridement and exchange of 
 137 
 
mobile parts for acute infections and two-stage revision for chronic infections are consistent 
with those previously reported in the literature especially where a clear protocol has been 
followed. (Brandt et al., 1997, Crockarell et al., 1998, Tattevin et al., 1999, Meehan et al., 
2003, Marculescu et al., 2006, Aboltins et al., 2007, Berdal et al., 2005, Zimmerli et al., 1998, 
Hofmann et al., 2005, Hsieh et al., 2004, Meek et al., 2003, Younger et al., 1997, Toulson et 
al., 2009) It is of note, though, that the inclusion and exclusion criteria, as well as 
management protocols, varied among those studies, occasionally including all four types of 
periprosthetic infections rather than acute or chronic infections only. Additionally, some of 
the studies did not differentiate between hips and knees when reporting their results which 
resulted in a wide range of infection rates. (Table 5.2) 
Table 5.2 Previous studies reporting prosthesis retention following irrigation and 
debridement treatment 
Author Infection 
Site 
Number 
of cases 
Exchange of 
mobile parts 
Retention rate Follow-up in 
years 
(Azzam et al., 2010) Hip/Knee 104 29% 44% 5.7 
(Aboltins et al., 2007) Hip/Knee 20 Partly 90% 2.7 
(Aboltins et al., 2011) Hip/Knee 17 Yes 88.2% 2.3 
(Berdal et al., 2005) Hip/Knee  18 Yes 94.5% 1.8 
(Cobo et al., 2011) Hip/Knee  103 Yes 54.3% 2.4 
(Crockarell et al., 1998) Hip 42 No 26% 6.3 
(Estes et al., 2010) Hip/Knee 20 Yes 90% 3.5 
(Klouche et al., 2011) Hip 12 Partly 75% 3.3 
(Krasin et al., 2001) Hip 7 No 71% 2.5 
(Marculescu et al., 2006) Hip/Knee   99 48% 60% 2 
(Martinez-Pastor et al., 2009) Hip/Knee 47 Yes 74.5% 1.2 
(Meehan et al., 2003) Hip/Knee 19 26% 89.5% 3.9 
(Tattevin et al., 1999) Hip/Knee 34 No 38.2% 1.6 
(Tintle et al., 2009) Hip/Knee 8 Yes 100% 3.1 
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(Tsukayama et al., 1996) Hip 41 Yes 68% 6.8 
(Van Kleunen et al., 2010) Hip/Knee  18 72% 72.2% 2.6 
(Zimmerli et al., 1998) Hip/Knee 8 No 100% 2.9 
The current study Hip 26 Yes 75% 6.6 
 
On the other hand, single stage revisions for chronic infections are regaining momentum and 
our results certainly reflect a strict protocol which has led to high rates of eradicating 
infection. (Callaghan et al., 1999, Joulie et al., 2011, Moyad et al., 2008, Raut et al., 1995, 
Winkler et al., 2008, Rudelli et al., 2008) Our single stage direct exchange protocol for 
acutely infected cementless THAs is a novel approach which has not yet gained popularity, 
but presents a time-limited opportunity to remove the implants prior to ingrowth in a 
cementless THA (Hansen et al., 2013). In comparison with aggressive debridement with 
exchange of mobile parts in cemented THAs, it showed superior results for eradication of 
infection (79% vs. 77%) with a single operation whereas a few of the cases in the 
debridement group required several wash outs with the additional soft tissue trauma caused 
before eradication of infection. 
We agree that only through the use of standardised terminology that an international language 
of comparative results will be feasible and therefore, we support efforts made to standardise 
the definition of PJI (Oussedik et al., 2012, Zimmerli and Ochsner, 2003, Giulieri et al., 2004, 
Workgroup, 2011). However, in view of the heterogeneity of clinical presentation and 
variability of diagnostic tests’ validity and reliability in diagnosing infection, the debate for a 
common strategy of treatment is yet to be finalised. 
5.6 Conclusion 
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In conclusion, our data support the important role of specialist centres and present a clear 
protocol for treating periprosthetic hip arthroplasty infections against which other modalities 
can be tested. 
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Chapter 6 
 
Discussion 
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6.1 Summary of Findings and Future Challenges 
Despite the advances in prevention, diagnosis and treatment of PJIs, overall management 
remains challenging for the surgeon, patient and healthcare systems. In this thesis, having 
conducted a thorough literature review confirmed that prevention is the best strategy for 
managing PJIs. On the other hand, reaching a consensus recently to what constitutes a PJI has 
marked an important achievement in creating a platform for surgeons to communicate and 
work simultaneously in managing infections. Preventative strategies including the use of 
triclosan coated sutures and tranexamic acid have been explored in an RCT and meta-analysis 
of level one studies respectively. The most up to date diagnostic tools for PJIs have been 
discussed in the literature review. The role of single versus two stage revisions for chronic 
PJIs as well as the impact of undergoing treatment at a centre of excellence on infection-free 
survival has also been investigated in this thesis. A summary of our findings and future 
considerations are detailed in the following sections. 
6.1.1 Prevention of PJIs 
In order to prevent microbial colonisation of suture material in operative wounds, the 
triclosan coated VPS was introduced in 2002 and this has led to a reduction in both bacterial 
adherence to sutures and microbial viability in vitro and in animal models. Similarly, VPS 
had positive effects on wound healing and infection rates in a number of meta-analyses and 
RCTs conducted in specialties such as general and vascular surgery. However, negative 
effects such as dermatitis, skin irritation, allergic reactions and haematomas have also been 
described. Taking into consideration that no trials to date have investigated the benefits of 
using VPS for wound closures in orthopaedic surgery, we hypothesised that VPS may result 
in better wound healing characteristics and fewer infections than standard vicryl sutures in 
total hip and knee arthroplasty wound closures. To investigate this, we conducted a single-
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centred, double-blind RCT to compare the healing characteristics of wounds closed using 
VPS and standard vicryl sutures in patients undergoing primary total hip or total knee 
arthroplasty. The primary outcome was the ASEPSIS wound scoring system and secondary 
outcomes included time for wound closure, length of operation, length of hospital stay, pain 
assessment and associated complications. Despite the premature termination of this study due to 
the unavailability of the sutures after December 2014, the study findings were significant to 
reject our hypothesis as the sensitivity analysis using the Mann Whitney test (P=0.036) as 
well as assessment of the wound complications at the last follow up showed significantly 
higher wound complication rates in the VPS group (P=0.03). We concluded that in hip and 
knee replacement surgery where rates of SSI are low in comparison to abdominal surgery, 
negative effects such as dermatitis, skin irritation, allergic reactions and haematomas may 
become more important and hence the advice against using the VPS in such surgeries. 
However, there certainly is a need for larger studies to substantiate our findings in hip and 
knee arthroplasty surgery and other subspecialties of orthopaedic surgery. Another area of 
interest requiring further research is the combination of triclosan and antibiofilms as coatings 
for implants to inhibit bacterial adhesion and biofilm formation. An example of biologically 
active antibiofilms includes deoxyribo-nuclease (DNase) I and Dispersin B which act by 
interrupting the physical integrity and increasing the permeability of the biofilm matrix 
(Kaplan, 2009, Darouiche et al., 2009). An in-vitro study of the efficacy of triclosan and 
Dispersin B coated vascular catheters showed synergistic antimicrobial and antibiofilm 
activity against Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli, 
significantly reducing bacterial colonisation (P < 0.05) (Darouiche et al., 2009). Antibiotics 
and metal ions such as silver have also been utilised as surface coatings to prevent biofilm 
formation and are worth further investigations for efficacy and durability (Park et al., 2009).  
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TXA has gained popularity in reducing perioperative blood loss and transfusion requirements 
in THA surgery. On the other hand, numerous studies have shown that allogeneic blood 
transfusion increases the risk of SSI and respiratory tract infections. However, no studies to 
date have investigated the direct relationship between TXA and wound complications 
including SSIs. Therefore, we conducted a meta-analysis to investigate the hypothesis that 
using TXA may result in less wound complications including SSIs after primary THA. The 
methods for this study were based on the Cochrane methodology for conducting systematic 
reviews and meta-analyses. The primary outcome measure was wound complications 
including infections. The secondary outcome measures were blood loss, the proportion of 
patients who had allogeneic blood transfusion, the amount of blood units transfused per 
patient, functional hip outcome measures, general quality of life outcome measures and 
complications such as DVTs, PEs, any thrombosis, renal failure, reoperation due to bleeding, 
non-fatal myocardial infarction, stroke and death. A comprehensive list of online databases 
was searched for RCTs published in any language from 1966 to April 2016. The search 
resulted in 21 RCTs which were appraised then data were extracted and analysed 
accordingly. The most significant result of this meta-analysis is the consistency of TXA in 
reducing wound complications after primary THAs with no heterogeneity in the studies 
included. The effect of TXA on wound healing has never been analysed in a meta-analysis of 
level one studies previously which could be an important addition to the advantages of using 
TXA in hip replacement surgery. Similarly, TXA reduced blood loss and allogeneic blood 
transfusion requirements. However, there has been significant heterogeneity among the 
studies evaluating these outcomes which necessitates careful interpretation of TXA effect in 
this context. Additionally, future randomised trials of sufficient power should be designed to 
examine the efficacy and safety of TXA in revision hip surgery and its efficacy in 
comparison to other blood conservation methods.  
 144 
 
The growing incidence of resistant microorganisms has also led to the introduction of new 
antibiotics with good antimicrobial and pharmacokinetic properties. Antimicrobial therapy 
and eradication of infection also improved with the introduction of antibiotic loaded cement. 
However, using polymethylmethacrylate as the standard material for delivering depot 
antibiotics has raised concerns as it is surface friendly to biofilm-forming bacteria. Therefore, 
many biodegradable materials have been evaluated as alternatives including protein-based 
materials (collagen, fibrin, thrombin, clotted blood), bone-graft, bone-graft substitutes and 
extenders (hydroxyapatite, beta-tricalcium phosphate, calcium sulphate, bioglass), and 
synthetic polymers (Sukeik and Haddad, 2009a). Unfortunately, considering the limited 
clinical data that is currently available, the use of these materials is still experimental and 
clinical application should be cautious. 
6.1.2 Diagnosis of PJIs 
While the clinical diagnosis of PJI is not always straightforward, the lack of a gold standard 
test makes its diagnosis challenging. Our literature review demonstrated that the combination 
of various diagnostic tests into the MSIS algorithm has improved consensus and approach to 
managing PJIs. However, molecular biology continues to develop, and may well have an 
essential role in the future in identifying infection with the advantage of reducing the amount 
of time necessary to obtain results and commencing treatment. Synovial biomarkers under 
investigation for future application include cytokines such as IL-1β, IL-6, IL-8, IL-17, TNF-
α, interferon-δ, and vascular endothelial growth factor, human β-defensin-2 (HBD-2) and 
HBD-3, and cathelicidin LL-37 (Chen et al., 2014). It is important to note that the main 
disadvantage of synovial biomarkers is that these tests depend on the availability of synovial 
fluid, and synovial fluid cannot be aspirated from a joint in all PJI cases. Moreover, some of 
the inflammatory biomarkers may represent any type of inflammatory process in the 
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prosthetic joint such as an adverse reaction to foreign material. Therefore, these tests may not 
be specific enough for PJI. New technologies based on biofilm targeting and the applications 
of metabolomics are currently underway. This includes biofilm visualisation and sequencing-
based biomolecular methods, PCR-based electron spray ionization time-of-flight mass 
spectrometry (ESI-TOF-MS), matrix-assisted laser desorption ionisation time-of-flight mass 
spectrometry (MALDI-TOF/MS) (Bizzini et al., 2010, Jacovides et al., 2012) and BioFire 
Diagnostic’s FilmArray system (Altun et al., 2013). Earlier PCR-based assays led to a higher 
rate of false-positives due to contamination and higher false-negatives because the probes 
could not cover the wide spectrum of pathogens responsible for infection. The use of PCR-
based ESI-TOF-MS improves the utility of PCR in diagnosing PJI. For example, Jacovides 
(Jacovides et al., 2012) reported that using such systems not only verified positive 
conventional culture results, but also detected an organism in four out of five cases of PJI that 
was thought to be culture-negative. Additionally, 88% of the revision cases that were 
presumed aseptic were found to be cases that had a subclinical infection. MALDI-TOF/MS 
identifies bacteria via analysis of their macromolecular profile. Laser ionisation is used to 
measure the charge and molecular mass of the bacterial surface proteins. Since individual 
bacterial species have a unique mass-to-charge ratio, the obtained information is cross-
matched with a bacterial spectra database (such as MALDI Bio-typer database) to identify the 
causative pathogen for PJI (Bizzini et al., 2010). This method is rapid and cost-effective, and 
has been performed on different bodily fluids (including periprosthetic joint fluid) with high 
agreement compared with standard methods for bacterial identification (El-Bouri et al., 
2012). Another alternative to those methods is the next generation sequencing technology 
which enables billions of DNA strands to be sequenced in parallel, minimising the need for 
fragment cloning (Chiu, 2013). Unlike methods based on PCR, it does not rely on set 
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parameters or a panel of targets. Results are produced in 10 hours to 2 days but this 
technology is yet to be tested in diagnosing PJIs.  
6.1.3 Treatment of PJIs 
Two-stage revision remains the standard for treatment of chronic TKA infections because 
many series report the successful eradication of a PJI in more than 90% of patients using this 
approach. On the other hand, single-stage revision in selected cases has become an appealing 
alternative because it involves only one surgical procedure and, if comparably effective, is 
associated with less patient morbidity and potentially improved functional outcomes and less 
expense. At our institution, we carry out single-stage TKA revisions for chronic infections in 
very selected circumstances and therefore, our hypothesis was that a single-stage approach 
would be as effective as a two-stage approach if implemented in the correct patient 
population. We performed a retrospective cohort analysis of a prospectively compiled register 
of all 102 patients diagnosed with chronic infected TKAs of whom 28 (27%) were treated 
using a single-stage approach and 74 (73%) were treated using a two-stage approach between 
2004 and 2009. Results showed that none of the patients in the single-stage revision group 
developed recurrence of infection, and five patients (7%) in the two-stage revision group 
developed reinfection (p = 0.16).  Those patients, however, underwent a further two-stage 
revision procedure and had their infections eradicated at last follow-up. The Knee Society 
score was also higher in the single-stage group at 2 years than in the two-stage group (mean 
88 (range 38-97) versus 76 (range 29-93, p < 0.001). We concluded that the use of single-
stage revision surgery in chronic TKA infections provides high rates of infection-free 
survival when patients are carefully selected. However, larger, multicenter, prospective trials 
are called for to validate our findings. 
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Specialist tertiary centres dealing with PJIs on a regular basis using a multidisciplinary 
approach and clearly defined protocols may improve infection eradication rates and 
contribute to standardising management of PJI after THA. Our hypothesis was that treatment 
of infections at a centre of excellence improves overall infection rates. We investigated this 
by performing a retrospective cohort analysis of a prospectively compiled register of all 204 
patients diagnosed with infected THAs (127 primaries, 77 revisions) and treated according to 
our protocol between 1999 and 2009. In acutely infected cemented THAs where the 
components are well fixed, we perform an aggressive open débridement with exchange of 
mobile parts and retention of the implant. In acutely infected cementless THAs, when the 
infection is secondary to haematogenous spread in previously well functioning and well fixed 
implants, we follow the same protocol for cemented prostheses. However, in acute 
postoperative infections, once the debridement is complete we then proceed to a direct 
exchange single-stage cementless THA. In chronic PJIs, the standard treatment is a two-
staged revision procedure. However, in a highly selected subset of patients, a single-stage 
approach is utilised and has proven to provide high rates of eradicating infections. At last 
follow-up, 188 of the 204 patients (92%) achieved eradication of their infections and returned 
to their expected functional level with no evidence of recurrence or loosening, wearing away, 
or malpositioning on follow-up radiographs. Our results compare well with various treatment 
strategies reported in the literature. We therefore concluded that management of PJI at 
tertiary centres with the appropriate setup of a multi-disciplinary team dealing with infection 
on a regular basis improves infection-free survival and patient outcomes. The next step would 
be to collaborate at an international level between these centres to establish a common 
pathway for managing PJIs taking into consideration local differences in microbiology but 
eliminating patient, surgeon and healthcare system factors which often prevent reaching a 
consensus. 
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Alongside the above recommendations for treatment of PJIs, a number of adjuvant therapies 
are currently being tested and may have an essential role in the future in improving treatment 
of PJIs. These include bacteriophage (Kaur et al., 2014) and photodynamic therapy (Saino et 
al., 2010), the use of magnetic (Ercan et al., 2011) or electric currents (Ueshima et al., 2002), 
shockwave treatment (Hansen et al., 2012) and bioactive glass (Drago et al., 2013). 
6.1.4 Conclusion 
In summary, there are continued efforts to advance diagnostics and therapeutic strategies in 
treating PJIs but this remains much more expensive then prevention as a management 
strategy. Using triclosan coated sutures does not have a protective effect against infection. On 
the contrary, it has been associated with higher rates of wound complications and infections. 
TXA has led to a reduction in the risk of developing wound complications including 
infections compared to the control group. The use of treatment strategies such as the single 
stage approach in selected patients and treating PJIs at specialist centres also contribute to 
successful treatment of PJIs.   
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Department of Orthopaedics 
University College Hospital 
Ground Floor Central           
250 Euston Road 
NW1 2PG 
      Tel: 0845 155 5000 ext. 9413 
 
Appendix 2.1 Patient Information Sheet  
 
A randomised controlled trial of triclosan coated sutures in primary total hip and total knee 
arthroplasty 
Dear Sir or Madamme, 
You are being invited to take part in a research study. Before you decide if you want to take part, it is 
important for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you wish. Ask us if there 
is anything that is not clear or if you would like more information. It is totally voluntary and up to you 
to decide whether or not to take part. If you decide to take part you will be given this information 
sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
 
Thank you for reading this. 
 
1. What is the purpose of the study? 
 
Although safer than ever, infections after hip and knee replacements remain a challenging problem. 
Managing such infections often requires a long course of treatment and can lead to unhappy patients 
with poor function of the joint. We are always looking for ways to prevent infection, as it has been 
proven that prevention, rather than treatment, provides the best outcome for our patients. 
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The purpose of this study is to find out whether sutures (stitches) coated with an antiseptic agent 
called triclosan are able to reduce infections within a surgical wound, in people having total hip and 
total knee replacements. Triclosan is not a new drug and has been used for more than 30 years in 
toothpaste, cosmetics and antiseptic soaps. Triclosan-coated sutures have been successfully used to 
reduce infections after heart surgery, abdominal surgery and neurosurgery. We hope that the use of 
triclosan-coated sutures will work in a similar way when used in total hip and total knee replacements. 
 
To be able to determine the effect of triclosan-coated sutures in total hip and total knee replacements, 
we need to compare the number of infections between those who are given the new suture and those 
who are given regular sutures.  
 
If you agree to enter this study, you will be placed in one of the two groups. One group of participants 
will receive triclosan-coated sutures during surgery and a second group will receive an ordinary suture 
without triclosan. The group you will go into will be chosen at random (like a spin of a coin). Neither 
you nor the investigator will know which group you are in. At the end of your operation the deep 
layers of the wound (which you will not be able to see) will be stitched using either the triclosan-
coated suture or the ordinary suture. The outside skin (which you will be able to see) will be closed as 
normal, using clips for both groups. This is the only difference between the two groups. You will then 
receive our standard postoperative treatment, for people undergoing total hip or total knee 
replacements. 
 
2. Why have I been chosen? 
 
Your surgeon has decided that you need a total hip or total knee replacement. We would like to invite 
you to take part in this study. We would like to recruit 420 patients, over a period of 24 months.  
 
3. What do I have to do? 
 
Your participation is voluntary but there will be an extra clinic for you to attend at the hospital 2 
weeks after the operation for inspection of the wound and removal of the skin clips rather than having 
that done at your GP surgery. Additionally, at the time of discharge you will be given a simple 
‘yes/no’ questionnaire regarding your wound, which you will be asked to complete and return in a 
pre-paid envelope two months after the operation. If you do decide to participate, you may withdraw 
at any time and you do not need to give a reason. Whatever you choose to do will not affect your 
treatment in anyway. 
  
4. What are the side effects of triclosan? 
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Minimal inflammation of the surrounding tissues, localised irritation when skin sutures are left in 
place for greater than 7 days (sutures used in this study will only be used to close the deep layers of 
the wound as detailed above), and slower absorption (>70 days) in tissues with poor blood supply as 
well as allergic reactions in the form of a rash or contact dermatitis have been reported with the use of 
triclosan. One study showed that triclosan-coated sutures increased the risk of wound separation in 
breast surgery. However, this was not supported by findings from other studies. Whilst rarely serious, 
the occurrence of any side effects will be sought while you are in hospital and at each subsequent 
hospital visit. You will be asked about hospitalisations, consultations with other medical practitioners 
and appropriate treatment will be provided according to the underlying problem. 
 
5. What are the possible benefits of taking part? 
 
We do not know for certain if triclosan-coated sutures will improve the wound healing or reduce 
infection rates in total hip and total knee replacements. However, there is a chance that these sutures 
will improve recovery time and joint function for hip and knee replacements. There may not be any 
benefit to you directly if you are placed in the group which will receive an ordinary suture without 
triclosan. 
 
6. What if something goes wrong? 
 
If you wish to complain, or have any concerns about any aspect of the way you have been approached 
or treated by members of staff you may have experienced due to your participation in the research, the 
National Health Service or UCL complaints mechanisms are available to you. Please ask your 
research doctor if you would like more information on this. In the unlikely event that you are harmed 
by taking part in this study, compensation may be available. 
If you suspect that the harm is the result of the Sponsor's (University College London) or the 
hospital's negligence then you may be able to claim compensation. After discussing with your 
research doctor, please make the claim in writing to Professor Fares Haddad who is the Chief 
Investigator for the research and is based at University College Hospital. The Chief Investigator will 
then pass the claim to the Sponsor's Insurers, via the Sponsor's office. You may have to bear the costs 
of the legal action initially, and you should consult a lawyer about this. 
 
7. Will my taking part in this study be kept confidential? 
 
If you consent to take part in the research any of your medical records may be seen by our research 
team for purposes of analysing the results. They may also be looked at by people from regulatory 
authorities to check that the study is being carried out correctly. Your name, however, will not be 
disclosed outside the hospital. Although this study is not conducted by your GP, your GP will be told 
of your participation in the trial.  
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8. What will happen to the results of the research study? 
 
At the end of the study, we will look at the results and compare the two groups of patients to see 
whether the triclosan-coated suture has any benefits. If it has, we will try to implement this in our 
clinical practice. We may publish the study in the medical journals to benefit other people. If we do 
so, you will not be identified in any report or publication. 
 
9. Who is organising and funding the research? 
 
This study is organised and funded by the Trauma and Orthopaedic Directorate at University College 
London Hospitals, and has not received any external funding. Your doctor will not be paid for 
including you in this study. 
 
10. Contacts for Further Information 
 
For any further information, please contact one of the following: 
 
Mr M Sukeik, Mr D George, Mr A Gabr, Mr R Kallala, Dr APR Wilson, Professor FS Haddad 
Department of Trauma and Orthopaedics 
University College London Hospital 
Ground Floor Central, 250 Euston Road 
London, NW1 2PG, Tel 020 7380 9413 Fax 020 7908 2060 
 
Thank you for considering taking part in this study. 
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Tel: 0845 155 5000 ext. 9413 
 
Appendix 2.2 Consent Form  
CONFIDENTIAL 
        UCL Project ID number:  
Patient Identification Number for this study:   Form version: 8.0  
 Version Date:  07/05/2013 
 
Title of project:  A randomised controlled trial of triclosan coated sutures in primary 
total hip and total knee arthroplasty 
   
Name of Principal investigator: Professor FS Haddad 
         
1. I confirm that I have read and understood the information sheet dated 07/05/2013 
(version 8.0) for the above study and have had the opportunity to ask questions. 
 
   
2.  I confirm that I have had sufficient time to consider whether or not want to be 
included in the study  
 
 
 
   
3. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
   
4. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my taking 
part in research. I give permission for these individuals to have access to my 
records. 
 
   
 
5. 
 
I agree that my GP is informed of my participation in the study. 
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6. 
 
I agree to take part in the above study. 
 
 
 
 
Name of Principal investigator: Professor FS Haddad 
 
__________________________ _________________   ________ 
Name of patient    Date     Signature 
 
 
________________________         _____________________  ________ 
Name of Person taking consent  Date     Signature 
(if different from researcher) 
 
________________________    
Name of the researcher to be contacted if there are any problems     
    
Comments or concerns during the study 
 
If you have any comments or concerns you may discuss these with the investigator.   If you wish to 
go further and complain about any aspect of the way you have been approached or treated during the 
course of the study, you should write or get in touch with the Complaints Manager, UCL hospitals.  
Please quote the UCL project number at the top this consent form. 
 
1 form for Patient;  
1 to be kept as part of the study documentation,   
1 to be kept with hospital notes 
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University College Hospital 
Ground Floor Central           
250 Euston Road 
NW1 2PG 
Tel: 0845 155 5000 ext. 9413 
  
APPENDIX 2.3 GP Questionnaire 
 
Dr        Date:  
GP Surgery 
     
Dear Dr, 
 
Re: Patient name      Hospital No:    Date of birth: 
 
University College London Hospital is running a randomised controlled trial to compare the healing 
characteristics of polyglactin 910 triclosan (antibacterial) coated sutures (treatment of interest) and 
polyglactin 910 sutures (routine care) in patients aged 18 or over undergoing primary unilateral hip 
and knee arthroplasty. 
Your patient, patient name, agreed to take part in the trial and was randomised to receive treatment of 
interest / routine care when they attended hospital on date of attendance. Apart from the use (or not) 
of the treatment of interest they will receive the standard treatment for hip/knee replacements by 
hospital doctors. 
They will also attend our arthroplasty clinic at 2 weeks postoperatively for inspection of the wound and 
removal of the clips. Additionally, they will be sent a postal questionnaire survey at two months after 
hospitalisation, and then their involvement in the trial will end. The questionnaire will consist of an 
assessment of the patient’s wound healing. 
If you would like any further information about this project, please contact me using the details above. 
 
Yours sincerely 
Mr Mohamed Sukeik 
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APPENDIX 2.4 Data Collection Sheet 
 
      
 
 
 
Patient characteristics and risk factors affecting wound healing 
Diagnosis Gender Age  BMI Smoking Diabetes ASA  Length of 
operation 
(min) 
        
 
 
       
 
Surgical data and secondary outcomes measured  
Operation 
 
 
 
THR / TKR 
Time for wound closure 
(min) 
 
 
Surgeon level 
 
Consultant 
SpR 
Fellow 
Staff Grade 
 
Length of hospital stay 
(days) 
 
Type of anaesthesia 
 
(including local anaesthetic  
infiltration) 
General /Regional 
 
Local 
anaesthesia 
Yes / No 
 
Visual Analogue Score 
(1-10) 
Day 1 
 
Day 3 
 
Day 5 
 
Type of antibiotic  
prophylaxis and dose regimen 
 
  
LMWH prophylaxis 
 
Yes / No 
 
Type of prosthesis 
 
  
Number of sutures used 
 
 
 
 
Postoperative complications 
 
 
 
 
 
 
 
 
Complication Tick if present Complication Tick if present 
Nausea and vomiting  Chest infection 
 
 
Dizziness  Myocardial infarction 
 
 
Bleeding  Cerebrovascular accident 
 
 
Stiffness  Fracture 
 
 
Neurovascular damage  Dislocation 
 
 
Deep venous thrombosis 
 
 Loosening of prosthesis  
Pulmonary embolism 
 
 Mortality  
Other complications/ Serious  
adverse events 
 
   
 
Randomisation code: 
 
ASEPSIS Score (primary outcome): 
Length of follow up: 
Patient label 
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APPENDIX 2.5 Post-discharge Questionnaire 
 
Dear Patient, 
 
Re: Follow up on the progress of your wound: 
 
Hospital Number:   Date of operation:  
 
We saw you in hospital some time ago to see how your wound site was getting on.  As some wounds cause a 
few problems once a patient goes home, we’d be grateful if you would fill out this questionnaire if your 
operation was at least 1 month ago.  The information you give us will help us to plan and improve our patient 
care. 
 
 
Have the wounds healed without any problems at all?        Yes       No  
 
If “yes” please ignore the following questions.  If “no” please answer the following: 
 
 Has the wound been red?          Yes       No   
 Has the wound discharged clear yellow fluid?        Yes       No   
 Has the wound discharged pus?         Yes       No  
 Has the wound broken open?          Yes       No  
 Have you been given antibiotics for wound infection?       Yes       No 
 Has a district nurse had to dress the wound?         Yes       No  
 Has a doctor opened/drained an abscess?        Yes       No 
 Have you been admitted to hospital elsewhere?         Yes       No      
 Has the wound been opened and cleaned under general anaesthetic in hospital?   Yes       No     
 
Thank you for your help 
 
Yours sincerely, 
 
A.P.R. Wilson, MA, MD, FRCPath, FRCP 
Consultant Microbiologist 
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APPENDIX 2.6 MHRA Letter 
 
Subject: RE: Scope - protocol review - coated polyglactin 910 sutures with triclosan - Our ref: 
E/2010/0691 
Date: Tue, 20 Jul 2010 14:37:49 +0100 
From: Daniella.Smolenska@mhra.gsi.gov.uk 
To: msukeik@hotmail.com 
 
Dear Mr Sukeik 
  
Thank you for your email below.  I can confirm that a product which is primary intended to act as a 
suture will most likely be regulated as a medical device. 
  
From our telephone conversation last week I understand that the coated sutures subject to the 
investigation are CE marked. As such I can confirm that as long as the devices are CE marked for the 
purpose under investigation there will be no requirement to obtain MHRA authorisation for this study. 
  
Please note that whilst we are willing to give any help and advice we can, any views given by us on 
the interpretation of the Medical Device Regulations represent our best judgement at the time, based 
on the information available. Such views are not meant to be a definitive statement of law, which may 
only be given by the Courts. Accordingly we would always advise you to seek the views of your own 
professional advisors. 
  
I hope that this has answered your questions, however if you require further guidance please 
contact me again. 
  
Kind regards 
Daniella 
  
Daniella Smolenska  
Regulatory Affairs Manager  
Market Towers room 8/2-A07  
1 Nine Elms Lane  
Vauxhall  
LONDON SW8 5NQ  
Tel: +44 (0) 20 7084 3363  
Fax: +44 (0) 20 7084 3112  
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APPENDIX 2.7 UCLH Research and Development 
Department Approval 
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